<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Transfusion Clinique et Biologique via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Transfusion Clinique et Biologique' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Transfusion+Clinique+et+Biologique&t=Transfusion+Clinique+et+Biologique&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 17:42:13 +0100</lastBuildDate>
        <item>
            <title>[Regular versus lapsed donors: Sociodemographic differences and motivational factors.]</title>
            <link>http://www.medworm.com/index.php?rid=5644059&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22285572%26dopt%3DAbstract</link>
            <description>CONCLUSION: Workers, senior management and higher intellectual professions should be targeted uppermost, in order to convert them in regular donors. Finally, concerning motivations, the social pressure applied to lapsed donors for their first blood donation appears crucial, whereas regular donors have internalized their motives, more often altruistic and community motivations.
    PMID: 22285572 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5644059</comments>
            <pubDate>Fri, 27 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5644059</guid>        </item>
        <item>
            <title>[Practice assessment in platelet transfusions.]</title>
            <link>http://www.medworm.com/index.php?rid=5644060&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22284451%26dopt%3DAbstract</link>
            <description>CONCLUSION: Globally, with regard to transfusion threshold, guidelines were followed in 71%, and 93% in oncological units. Transfusion efficacy, attested by post-transfusion platelet efficiency was above 20% in 59% of the cases. These data highlight a good respect of the transfusion thresholds in the usual platelets-consuming units, but raise the question of the dose, often under those proposed by the guidelines.
    PMID: 22284451 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5644060</comments>
            <pubDate>Wed, 25 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5644060</guid>        </item>
        <item>
            <title>[Traceability of labile blood products in Morocco: Experience of the Ibn-Sina hospital of Rabat between 1999 and 2010.]</title>
            <link>http://www.medworm.com/index.php?rid=5626676&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22269085%26dopt%3DAbstract</link>
            <description>CONCLUSION: Feedback information about traceability in Ibn-Sina hospital remains very poor despite the measures used. Other actions, such as continuous education courses, low enforcement and informatisation should be considered.
    PMID: 22269085 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5626676</comments>
            <pubDate>Sat, 21 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5626676</guid>        </item>
        <item>
            <title>[Use of platelet concentrates: A regional experience.]</title>
            <link>http://www.medworm.com/index.php?rid=5626675&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22269086%26dopt%3DAbstract</link>
            <description>CONCLUSION: More frequent PPC use, with comparable therapeutic efficacy, could be interesting in a context of increasing platelet concentrates consumption in health care establishments. Moreover, prescribers did not seem to be against the idea. An information pamphlet on platelet concentrates was drafted and distributed to prescribers in order to promote the prescription of PPC. A second assessment is planned to measure the impact of this communication.
    PMID: 22269086 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5626675</comments>
            <pubDate>Sat, 21 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5626675</guid>        </item>
        <item>
            <title>[Guidelines for blood transfusion teaching to medical laboratory technology students.]</title>
            <link>http://www.medworm.com/index.php?rid=5626674&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22269087%26dopt%3DAbstract</link>
            <description>Authors: Moncharmont P, Tourlourat M, Fourcade C, Julien E, Peyrard T, Cabaud JJ
    Abstract
    PURPOSE OF THE STUDY: The new French law about clinical laboratory medicine, the requirements of the ISO/CEI 15189 standard, the numerous abilities expected from the medical laboratory technologists and their involvement in blood bank management has led the working group &quot;Recherche et démarche qualité&quot; of the French Society of Blood Transfusion to initiate an inventory of blood transfusion teaching syllabus for medical laboratory technology students and to propose transfusion medicine teaching guidelines. MATERIAL AND METHODS: Seven worksheets have been established for that purpose including red blood cell antigen typing and antibody screening, blood sampling in immunohaematology, automatio...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5626674</comments>
            <pubDate>Sat, 21 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5626674</guid>        </item>
        <item>
            <title>C35T mutation could slightly decrease the activity of human α-(1,2)-fucosyltransferase.</title>
            <link>http://www.medworm.com/index.php?rid=5626677&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22266267%26dopt%3DAbstract</link>
            <description>CONCLUSION: These results suggested that FUT1 C35T was a polymorphism in the Chinese population and did not affect its mRNA transcription, but could slightly decrease the activity of human α-(1,2)-fucosyltransferase in vitro.
    PMID: 22266267 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5626677</comments>
            <pubDate>Fri, 20 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5626677</guid>        </item>
        <item>
            <title>[Qualitative evaluation of blood products records in a hospital.]</title>
            <link>http://www.medworm.com/index.php?rid=5626678&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22261347%26dopt%3DAbstract</link>
            <description>CONCLUSION: Although blood products traceability has good quantitative results, the recorded documentation is not qualitative. In our study, data entry errors are similar in electronic or paper records, but the global failure rate is lesser in electronic records because omissions are controlled.
    PMID: 22261347 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5626678</comments>
            <pubDate>Tue, 17 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5626678</guid>        </item>
        <item>
            <title>From whole blood to component therapy: The economic, supply/demand need for implementation of component therapy in sub-Saharan Africa.</title>
            <link>http://www.medworm.com/index.php?rid=5383368&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22037104%26dopt%3DAbstract</link>
            <description>Authors: Erhabor O, Adias TC
    Abstract
    Blood may be transfused as whole blood or as one of its components. Because patients seldom require all of the components of whole blood, it makes sense to transfuse only that portion needed by the patient for a specific condition or disease. This treatment, known as &quot;blood component therapy&quot;, allows several patients to benefit from one unit of donated whole blood. Blood components include red blood cells, plasma, platelets, and cryoprecipitate. A considerable literature has accumulated over the past decade indicating that leukocytes present in allogeneic cellular blood components, intended for transfusion, are associated with adverse effects to the recipient. These include the development of febrile transfusion reactions, graft-versus-host dis...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5383368</comments>
            <pubDate>Fri, 28 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5383368</guid>        </item>
        <item>
            <title>[Back to the future: A fiction dealing with pathogen inactivation of blood products.]</title>
            <link>http://www.medworm.com/index.php?rid=5383367&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22037105%26dopt%3DAbstract</link>
            <description>CONCLUSION: Such a fiction story opens the debate on a series of fundamental questions that could be addressed during the paradigm shift that is expected by introducing universal pathogen inactivation of blood products.
    PMID: 22037105 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5383367</comments>
            <pubDate>Fri, 28 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5383367</guid>        </item>
        <item>
            <title>Relevance of RH variants in transfusion of sickle cell patients.</title>
            <link>http://www.medworm.com/index.php?rid=5348144&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22024128%26dopt%3DAbstract</link>
            <description>Authors: Noizat-Pirenne F, Tournamille C
    Abstract
    Transfusion remains the main treatment of sickle cell disease patients. Red cell alloimmunization is frequent because of the antigen disparities between patients of African descent and donors of European ancestry. Alloimmunization is associated with severe hemolytic transfusion reaction, autoantibody formation, and difficulties in the management of transfusion compatibility. Beside common antigens, a number of different RH variant antigens found in individuals of African descent can be involved in alloimmunization. If some variants, such as Hr(S) negative antigens, are known to prone significant alloantibodies and delayed hemolytic transfusion reactions, it is not clear whether all the described variants represent a clinical risk fo...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5348144</comments>
            <pubDate>Sat, 22 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5348144</guid>        </item>
        <item>
            <title>[Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: Report of 30 cases.]</title>
            <link>http://www.medworm.com/index.php?rid=5348149&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22019606%26dopt%3DAbstract</link>
            <description>CONCLUSION: We conclude that HH patients treated with bimonthly EA achieved iron depletion in less than 1year under good condition of tolerance. These data support the use of EA in patients with a severe iron overload, since it may reduce the number of the procedures as well as the duration of the iron depletion therapy.
    PMID: 22019606 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5348149</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5348149</guid>        </item>
        <item>
            <title>[The contribution of persuasion social psychology to the retention of donors: Models to elaborate mailing to the donors.]</title>
            <link>http://www.medworm.com/index.php?rid=5348148&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22019607%26dopt%3DAbstract</link>
            <description>Authors: Callé N, Plainfossé C, Georget P, Sénémeaud C, Rasonglès P
    Abstract
    The supply of blood cell products required from the National French Blood Institute (Établissement français du sang [EFS]) relies upon regular blood donors. Contact with donors, tailored to individuals as much as possible, helps them to donate on a regular basis. To communicate as efficiently as possible, the content of the mailings has to be adapted to individuals, each according to his/her motivation and the way he or she perceives and processes the information. Within the context of a research program conducted with the Psychology Department of the University of Caen Basse-Normandie, persuasive theoretical models from social psychology have been tested. These models allow adapting messages accord...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5348148</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5348148</guid>        </item>
        <item>
            <title>[Hematopoietic stem cells mobilization: State of the art in 2011 and perspectives.]</title>
            <link>http://www.medworm.com/index.php?rid=5348147&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22019608%26dopt%3DAbstract</link>
            <description>Authors: Bijou F, Ivanovic Z, Boiron JM, Nicolini F
    Abstract
    High-dose chemotherapy with stem cells support has largely improved in terms of hematopoietic stem and progenitor cells harvest procedures as well as in those, which target or manipulate the cellular composition of autologous graft. Optimal preparative regimens and supportive care had lead to better use of autologous transplantation procedure. For other patients assigned to hematopoietic transplantation, availability of allogeneic donors appears to be an interesting alternative source of hematopoietic stem cells. Since three decades, hematopoietic growth factors development has allowed mobilization optimization and collection of peripheral hematopoietic stem cells leading to reduced days of hospitalization and less blood ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5348147</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5348147</guid>        </item>
        <item>
            <title>[Optimization of a haematopoietic stem cell freezing process using a qualification protocol applicable to a programmable freezer.]</title>
            <link>http://www.medworm.com/index.php?rid=5348146&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22019609%26dopt%3DAbstract</link>
            <description>CONCLUSION: Here, we propose a validation protocol which is able to qualify a programmable freezer. This protocol can optimize the capability of the freezer and is able to prove its performance.
    PMID: 22019609 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5348146</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5348146</guid>        </item>
        <item>
            <title>[The contribution of persuasion social psychology to the retention of donors: The impact of labelling the previous donation.]</title>
            <link>http://www.medworm.com/index.php?rid=5348145&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22019610%26dopt%3DAbstract</link>
            <description>Authors: Callé N, Plainfossé C, Georget P, Sénémeaud C, Rasonglès P
    Abstract
    The supply of blood cell products requires from the National French Blood Institute (Établissement Français du Sang - EFS) to rely upon regular blood donors. Contact with donors, tailored to individuals as much as possible, helps them to donate on a regular basis. Within the context of a research program conducted with the Psychology Department of the Université de Caen Basse-Normandie, persuasive theoretical models from social psychology have been tested. These models allow adapting messages according to the motivation of donors. The content is centred on the previous donation, differently labelled according to two types of labelling: functional labelling and social labelling. Functional labelling...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5348145</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5348145</guid>        </item>
        <item>
            <title>Pathogen reduction: State of reflection in Ireland.</title>
            <link>http://www.medworm.com/index.php?rid=5112050&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21803629%26dopt%3DAbstract</link>
            <description>Authors: Murphy WG
    The Irish Blood Transfusion Service is currently assessing the feasibility and affordability of implementing pathogen reduction for platelets in Ireland. Since 2002, almost all plasma transfused in the country has been subjected to a pathogen reduction process in the form of Octaplas™ (or Uniplas™ for group AB recipients), manufactured from plasma from donors at the South Texas Blood and Tissue Center, San Antonio, TX, USA. Pathogen reduction of platelets for Ireland is driven by two major concerns: by the need for robust systems to prevent the transmission of any emerging transfusion transmissible infections or of diseases for which we do not currently test, and by the poor sensitivity and efficacy of even the most sensitive available approaches to bacterial con...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5112050</comments>
            <pubDate>Thu, 28 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5112050</guid>        </item>
        <item>
            <title>[Expected limits (and possible consequences) of pathogen inactivation technology.]</title>
            <link>http://www.medworm.com/index.php?rid=5112051&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21802331%26dopt%3DAbstract</link>
            <description>Authors: Lefrère JJ
    Pathogen reduction technology, now applicable to platelets and plasma, has limits that are already known, and potential or poorly defined other ones. We can distinguish limitations due to adverse events related to the technology itself or to recipient susceptibility, the limits of effectiveness depending on the target, the technology, organizational, economic and geographical limits.
    PMID: 21802331 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5112051</comments>
            <pubDate>Tue, 26 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5112051</guid>        </item>
        <item>
            <title>[Pathogen inactivation technologies: A complex but necessary debate.]</title>
            <link>http://www.medworm.com/index.php?rid=5112053&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21783399%26dopt%3DAbstract</link>
            <description>Authors: Andreu G, Cazenave JP, Garraud O, Lefrère JJ
    
    PMID: 21783399 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5112053</comments>
            <pubDate>Wed, 20 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5112053</guid>        </item>
        <item>
            <title>[Pathogen inactivation of platelets: Organization consequences for platelet transfusion.]</title>
            <link>http://www.medworm.com/index.php?rid=5112052&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21783400%26dopt%3DAbstract</link>
            <description>Authors: Chavarin P, Deputter C, Boussoulade F, Acquart S, Vidal M, Argaud C, Fabrigli P, Garraud O
    In the past few years, pathogen reduction technologies for labile blood products have been part of the enhancement of global transfusion safety regarding residual risks of transmitting infectious pathogens. Having carried out a feasibility study for the implementation of pathogen inactivation of platelet concentrates by means of the amotosalen/HCl/UVA (Intercept™) technology, and participated to a reinforced haemovigilance study, we took the opportunity to analyze the organization consequences for platelet concentrates inventory and distribution. This impact study first indicated that those novel needs forced the blood donation service, as well as the labile blood product preparation l...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5112052</comments>
            <pubDate>Wed, 20 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5112052</guid>        </item>
        <item>
            <title>[Pathogen reduction for platelets: Available techniques and recent developments.]</title>
            <link>http://www.medworm.com/index.php?rid=5019387&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21724440%26dopt%3DAbstract</link>
            <description>Authors: Andreu G
    The will to reach for blood components a microbiological safety comparable to that of plasma-derived drugs led to the development of numerous pathogen reduction research programs for red blood cells and\or platelets in the 1990s. A consensus conference organized in 2007 allowed to define the main steps and precautions to be taken for the implementation of these processes. In the specific case of platelet concentrates, three processes stay this day in the run, even if they are not at the same development stage. A process using ultraviolet C only is at the stage of preclinical studies. The Mirasol(®) process, based on the activation of riboflavin by exposure to ultraviolet A and ultraviolet B is CE marked (class IIb), and a clinical study was published in 2010. The Int...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5019387</comments>
            <pubDate>Thu, 30 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5019387</guid>        </item>
        <item>
            <title>[Pathogen inactivation in platelet concentrates: The French experience.]</title>
            <link>http://www.medworm.com/index.php?rid=5019389&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21719338%26dopt%3DAbstract</link>
            <description>Authors: Cazenave JP
    The transfusion of platelet concentrates is increasing in oncohematology patients due to chemotherapy and hematopoietic stem cell grafts. The transmission of pathogenic agents, viruses, parasites and especially bacteria with platelet concentrates stored at room temperature (20-24°C) is associated with a septic risk, partly prevented by bacterial detection. Photochemical inactivation of platelet concentrates, using a technique associating amotosalen and UVA, has been used for five years in a French region for the whole population and a large spectrum of patients, with efficacy and safety. Universal implementation of pathogen inactivation in labile blood products is a major and key step to improve safety against infection in transfusion.
    PMID: 21719338 [PubMed -...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5019389</comments>
            <pubDate>Mon, 27 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5019389</guid>        </item>
        <item>
            <title>[Pathogen reduction of blood components: From financial issues to possible long-term consequences.]</title>
            <link>http://www.medworm.com/index.php?rid=5019388&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21719339%26dopt%3DAbstract</link>
            <description>Authors: Canellini G, Wasserfallen JB, Tissot JD
    Pathogen inactivation of blood products represents a global and major paradigm shift in transfusion medicine. In the next near future, it is likely that most blood products will be inactivated by various physicochemical approaches. The concept of blood safety will be challenged as well as transfusion medicine practice, notably for donor selection or biological qualification. In this context, it seems mandatory to develop analytical economic approaches by assessing costs-benefits ratio of blood transfusion as well as to set up cohorts of patients based on hemovigilance networks allowing rigorous scientific analysis of the benefits and the risks of blood transfusion at short- and long-term.
    PMID: 21719339 [PubMed - as supplied by publi...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5019388</comments>
            <pubDate>Mon, 27 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5019388</guid>        </item>
        <item>
            <title>[Pathogen reduction: A clinician view.]</title>
            <link>http://www.medworm.com/index.php?rid=5019392&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21715208%26dopt%3DAbstract</link>
            <description>Authors: Socié G
    
    PMID: 21715208 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5019392</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5019392</guid>        </item>
        <item>
            <title>[Pathogen reduction for platelets: A debate.]</title>
            <link>http://www.medworm.com/index.php?rid=5019391&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21715209%26dopt%3DAbstract</link>
            <description>Authors: Moncharmont P, Py JY
    
    PMID: 21715209 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5019391</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5019391</guid>        </item>
        <item>
            <title>[Pathogen inactivation processes applicable to cellular products: The Canadian perspective.]</title>
            <link>http://www.medworm.com/index.php?rid=5019390&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21715210%26dopt%3DAbstract</link>
            <description>Authors: Delage G
    The highlights of the recent Canadian consensus conference on pathogen inactivation are summarized. Also, a brief summary of steps taken to date in order to implement these technologies is presented.
    PMID: 21715210 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5019390</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5019390</guid>        </item>
        <item>
            <title>[The training in transfusion medicine remains deficient in the centres of Francophone sub-Saharan Africa: Results of a preliminary study.]</title>
            <link>http://www.medworm.com/index.php?rid=4971821&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21676637%26dopt%3DAbstract</link>
            <description>Authors: Tayou Tagny C, Kapamba G, Diarra A, Ngandu C, Deneys V, Sondag-Thull D
    PURPOSE OF THE STUDY: To evaluate the needs in staff training in transfusion centres of Sub-Saharan Africa. MATERIAL AND METHODS: This preliminary study analyzed the training level of each personnel of four blood banks of Sub-Saharan Africa, their training fields, duration and training structures. RESULTS: The needs remain high in all the fields and are critical regarding the administration of blood transfusion services, equipment maintenance and clinical use of blood.
    PMID: 21676637 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4971821</comments>
            <pubDate>Sun, 12 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4971821</guid>        </item>
        <item>
            <title>[Acknowledged risks in transfusion and impact of taken measures on those risks.]</title>
            <link>http://www.medworm.com/index.php?rid=4971825&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21664163%26dopt%3DAbstract</link>
            <description>Authors: Garraud O
    Transfusion is indeed associated with risks that are diverse in nature. Besides, the society expects a risk- and vice-exempt transfusion. During the recent past years, there have been three levels of safety implementation in transfusion: a generalized risk assessment policy; a mastering of processes; standard quality engineering. However, these safety measures have impacts in several ways, such as management and organization, inventory, economics and possibly ethics. All these issues are addressed in the present essay as well as the possible effect of pathogen reduction procedures.
    PMID: 21664163 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4971825</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4971825</guid>        </item>
        <item>
            <title>[The place and moment of blood donation: Considerations on the organization of blood collection sites.]</title>
            <link>http://www.medworm.com/index.php?rid=4824376&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21458348%26dopt%3DAbstract</link>
            <description>Authors: Cunéo B, Pelletier B
    Conversations held with the staffs of blood collection sites at établissement français du sang (EFS) of several regions allow pinpointing their criticisms, expectations and suggestions. They concern, at the same time, the arrangement of sites and the donor circuit, the work organization and the management of the teams. This point seems major, underlining the role of local supervision, which is at once a technical expert and a manager, and the necessity to set up the conditions of a good cooperation, between professions where too many subdivisions still remain.
    PMID: 21458348 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824376</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824376</guid>        </item>
        <item>
            <title>[European Blood Alliance (EBA) and EuroNet TMS: What challenges for the transfusion of tomorrow?]</title>
            <link>http://www.medworm.com/index.php?rid=4824375&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21458349%26dopt%3DAbstract</link>
            <description>Authors: Folléa G, de Wit J, Rouger P
    The primary mission of the European Blood Alliance (EBA) is to contribute to the safety and efficiency of the supply of blood products, cells and tissues, in developing an active network of blood establishments in Europe (25 countries). Its strategic objectives are to improve performance (through working groups and projects funded by the European Union), to engage in regulatory affairs (particularly at the European Commission level) to promote best practices and to facilitate a network to collect and share knowledge and experiences. The main objective of EuroNet TMS, combining the blood scientific societies from more than 30 countries in Europe, is to update and publish regularly, intended for policymakers, a White Book on the transfusion chain fr...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824375</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824375</guid>        </item>
        <item>
            <title>[Clinical impact of length of storage before red blood cell transfusion.]</title>
            <link>http://www.medworm.com/index.php?rid=4824374&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21459646%26dopt%3DAbstract</link>
            <description>Authors: Lacroix J, Tucci M
    Presently, red blood cell units are stored up to 42days in France and Canada. Length of storage of red blood cell units is not based on clinical outcomes: it is rather based on a decision made by some experts in the 1940s that red blood cell units can be stored as long as the average hemolysis is lower than 1% and the proportion of red blood cells still alive 24hours post-transfusion is higher than 70%. Data reported recently suggest that transfusion with older red blood cell units may jeopardize the outcome of severely ill patients. In this paper, we comment the data already published on this question, and we summarize the randomized clinical trials presently on-going that were undertaken to address the relationship between length of storage of red blood ce...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824374</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824374</guid>        </item>
        <item>
            <title>[Allogeneic hematopoietic stem cell transplantations.]</title>
            <link>http://www.medworm.com/index.php?rid=4824373&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21466967%26dopt%3DAbstract</link>
            <description>Authors: Michallet M
    Allogeneic hematopoietic stem cell transplantation is the most widely used form of immunotherapy. The allogeneic immune effectors infused with the graft can recognize and eradicate the patients' tumoral cells. The curative potential of allogeneic hematopoietic stem cell transplantation is classically based on two mechanisms: the conditioning myelo-ablative or immunosuppressive inducing either the cytoreduction of tumoral cells or tolerance and the immune control mediated by allogeneic immune effectors (graft-versus-leukemia or tumor effect, GVL or GVT). Allogeneic hematopoietic stem cell transplantation is currently under important mutations because of better understanding of the GVT mechanisms and the development of new treatment techniques with : (a) allo-hemato...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824373</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824373</guid>        </item>
        <item>
            <title>[Predonation interview by a trained and authorized paramedical staff: Feasibility, reliability and safety.]</title>
            <link>http://www.medworm.com/index.php?rid=4824372&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21466968%26dopt%3DAbstract</link>
            <description>CONCLUSION: The study reported a weaker variability among nurses. Results show that nurses were able to perform predonation interviews with high reliability, without additional risk. The reproducibility of their answers in the field of recipient-risk evaluation was better than the physicians.
    PMID: 21466968 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824372</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824372</guid>        </item>
        <item>
            <title>[Technological evolutions in blood donation screening and their impact on the residual risk.]</title>
            <link>http://www.medworm.com/index.php?rid=4824371&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21466969%26dopt%3DAbstract</link>
            <description>Authors: Barlet V
    During the two last decades, the risk of viral transfusion transmission for some infectious agents (HIV, HCV, HBV and HTLV) has been markedly reduced by improved donor screening, improvements of serological assays and the implementation of minipool nucleic acid testing for HIV-1 and HCV viruses. However, implementation during the year 2010 of nucleic acid testing for the detection of HIV RNA, HCV RNA and HBV DNA in a single triplex assay may provide additional safety, especially after acute infection during the window period. New Procleix(®) Tigris(®) technology (Novartis) allow the French blood screening laboratories to answer their actual requirements in terms of security and throughput and to implement nucleic acid testing in case of emergent risks requiring a di...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824371</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824371</guid>        </item>
        <item>
            <title>[The immunological conflict in the transfusion-related acute lung injury or TRALI.]</title>
            <link>http://www.medworm.com/index.php?rid=4824370&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21470890%26dopt%3DAbstract</link>
            <description>Authors: Drouet C, Khoy K, Masson D, Bardy B, Giannoli C, Dubois V
    Despite its underrated incidence, transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related morbidity and mortality worldwide. The pulmonary edema in TRALI occurs in the course of the transfusion of apheresis products or erythrocyte concentrates. Its pathogenesis is attributed to the infusion of donor antibodies that recognize leucocyte antigens in the transfused host, with subsequent sequestration of leucocytes in the pulmonary vessels. It is also associated with the passive transfer of lipids and other biological response modifiers that accumulate during the storage or processing of blood components. The innate immunity and inflammatory kinins are key components. The knowledge of its et...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824370</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824370</guid>        </item>
        <item>
            <title>[Medical biology accreditation at EFS.]</title>
            <link>http://www.medworm.com/index.php?rid=4824369&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21470891%26dopt%3DAbstract</link>
            <description>Authors: Trapadoux F, Guitton Bliem C, Hergon E, Roubinet F
    The medical biology laboratory accreditation according to the Iso 15189 standard, which main lines are mentioned in the article, is henceforth becoming a statutory obligation in France. All laboratories must apply, at least partly, to the COFRAC, by 31(st) October 2012. The EFS has largely anticipated the necessary steps to reach this objective and has developed an approach based on six basic processes. To date, 24 laboratories of various technical fields are accredited and several other submissions are pending. The Iso 15189 standard requirements match those already implemented at the EFS with the Certification. The trade standard operating procedures are almost included in the risk control management. Through the involvement...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824369</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824369</guid>        </item>
        <item>
            <title>[Proteomics and transfusion medicine.]</title>
            <link>http://www.medworm.com/index.php?rid=4824368&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21470892%26dopt%3DAbstract</link>
            <description>Authors: Lion N, Prudent M, Crettaz D, Tissot JD
    The term &quot;proteomics&quot; covers tools and techniques that are used to analyze and characterize complex mixtures of proteins from various biological samples. In this short review, a typical proteomic approach, related to the study of particular and illustrative situation related to transfusion medicine is reported. This &quot;case report&quot; will allow the reader to be familiar with a practical proteomic approach of a real situation, and will permit to describe the tools that are usually used in proteomic labs, and, in a second part, to present various proteomic applications in transfusion medicine.
    PMID: 21470892 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824368</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824368</guid>        </item>
        <item>
            <title>[Techniques of preparation and indications of labile blood products.]</title>
            <link>http://www.medworm.com/index.php?rid=4824367&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21474355%26dopt%3DAbstract</link>
            <description>Authors: Clément S
    Labile blood products are obtained from samples of whole blood or aphaeresis. The techniques of preparation evolve with technological advances, which allow both an increasing automation and an intensification of the sanitary safety of the blood products. Over the last ten years, thanks to the availability of new technologies, several measures have been introduced in order to reduce the risk of transmission of pathogens and prevent the onset of transfusion-related acute lung injury (TRALI): leukoreduction, use of platelet storage solutions, inactivation of plasma and presumably of platelets in a very near future. The control of transfusion risk also depends on proper use of labile blood products. To assist the prescriber in his treatment options and to standardize pr...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824367</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824367</guid>        </item>
        <item>
            <title>[Seventeen years of haemovigilance in France: Assessment and outlook.]</title>
            <link>http://www.medworm.com/index.php?rid=4824366&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21474356%26dopt%3DAbstract</link>
            <description>Authors: Carlier M, Vo Mai MP, Fauveau L, Ounnoughene N, Sandid I, Renaudier P
    Since 1994, the French haemovigilance network has not stopped evolving. Based initially on the reporting of informations and incidents related to recipients, it quickly became interested in the procedures and other activities related to blood component transfusion, in order to improve blood safety. Despite some failures (under reporting, heavy declarative management), the French haemovigilance network is going to continue working on improving blood safety, both at the level of the recipients and the donors, and participate to the global improvement of quality of care.
    PMID: 21474356 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824366</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824366</guid>        </item>
        <item>
            <title>[Autoimmune haemolytic anemia: Diagnosis strategy and new treatments.]</title>
            <link>http://www.medworm.com/index.php?rid=4824364&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21474357%26dopt%3DAbstract</link>
            <description>Authors: Rigal D, Meyer F
    The pattern of autoimmune hemolytic anemia has changed significantly these last 15years. With regard to the diagnosis strategy, the use of gel filtration technique to perform the direct antiglobulin test (DAT) has decreased the number of autoimmune haemolytic anemias with negative tests results. In recent years, autoimmune haemolytic anemia increased in patients receiving purine nucleoside analogues, blood transfusions, solid organ transplantation or hematopoietic stem cells transplantation. These difficult autoimmune haemolytic anemia cases need to use new kinds of treatments. With regard to the treatment, very little progress was made this latter 50years. The discovery of the efficacy of anti-CD20 antibody in this disease represents a breakthrough. Nowdays,...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824364</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824364</guid>        </item>
        <item>
            <title>[Photochemical inactivation of pathogens in platelets and plasma: Five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety.]</title>
            <link>http://www.medworm.com/index.php?rid=4824363&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21474358%26dopt%3DAbstract</link>
            <description>Authors: Cazenave JP
    The transfusion of labile blood products is vital and essential for patients in absence of alternative treatment. Patients and doctors have always feared transfusion-transmitted infections by blood, blood components and blood-derived drugs. Photochemical inactivation of platelet concentrates and plasma, using a technique associating amotosalen and UVA, has been used for five years in a French region for the whole population and a large spectrum of patients, with efficacy and safety. It would seem wise to introduce labile blood products, submitted to pathogen inactivation by a technique already approved by a regulatory agency and not to wait for a perfect system including red blood cells concentrates. Universal implementation of pathogen inactivation in labile blood...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824363</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824363</guid>        </item>
        <item>
            <title>[Introducing marketing strategies and techniques into the field of voluntary blood donation, to meet the rise in blood demand.]</title>
            <link>http://www.medworm.com/index.php?rid=4824362&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21474359%26dopt%3DAbstract</link>
            <description>This article describes what has been achieved in the last three years and outlines the main steps in the social marketing planning process: analyzing the social marketing environment, defining target audiences and objectives, building and implementing strategies and action plans, evaluating and monitoring. On the way to self-sufficiency, while respecting donors, social marketing is additional to the work done by the blood collection staffs, communication teams, and volunteers. Social marketing is a complementary tool to the work done by the blood collection staff, communication teams and blood donation organizations and can help to meet the challenge of self-sufficiency while still allowing for the privacy and rights of donors.
    PMID: 21474359 [PubMed - as supplied by publisher] (Source...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4824362</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4824362</guid>        </item>
        <item>
            <title>[Blood platelets and biological response to 'danger' signals - and subsequent inflammation: Towards a new paradigm?]</title>
            <link>http://www.medworm.com/index.php?rid=4668463&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21444230%26dopt%3DAbstract</link>
            <description>Authors: Garraud O, Damien P, Berthet J, Arthaud CA, Hamzeh-Cognasse H, Cognasse F
    Blood platelets are cellular elements of primary haemostasis. During the last decade research on platelets has been subsequently based on this paradigm, with separate observations on issues such as the ability for platelets to bind infectious agents or even engulf them, to drop in counts in case of evolving infectious processes, etc. More recently, novel work has set up bases for novel functions for platelets, as members of functional immune cells, principally in innate immunity but capable of influencing adaptive immunity. Platelets are thus essential to haemostasis and to inflammation, questioning their essential functionality and the set up of a novel paradigm: could platelets be tissue-repairing cell...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4668463</comments>
            <pubDate>Sat, 26 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4668463</guid>        </item>
        <item>
            <title>[Cell-derived microparticules: Key players at the crossroad between inflammation and thrombosis.]</title>
            <link>http://www.medworm.com/index.php?rid=4668462&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21444231%26dopt%3DAbstract</link>
            <description>Authors: Sabatier F, Lacroix R, Leroyer AS, Cointe S, Dignat-George F
    Cell-derived microparticles are complex vesicular structures that can be shedded by activated or apoptotic endothelial cells. Cell-derived microparticles are composed of a phospholipid bilayer that exposes transmembrane proteins and receptors and encloses cytosolic components such as enzymes, transcription factors and mRNA derived from their parent cells. Thus, they behave as biological conveyors playing a key role in the tuning of vascular homeostasis. This review will address the potential of microparticles as efficient vectors of biological activities in pathologies. Based on the model of endothelial vesiculation, the first part of this review will develop the contribution of endothelial microparticles to coagulat...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4668462</comments>
            <pubDate>Sat, 26 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4668462</guid>        </item>
        <item>
            <title>[Evolution of neonatal transfusion practices: Current recommendations.]</title>
            <link>http://www.medworm.com/index.php?rid=4668485&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21440478%26dopt%3DAbstract</link>
            <description>Authors: Plaisant F
    Newborns and particularly preterm infants are a population at high risk of transfusion. The implementation of strategies to prevent transfusion by reducing blood loss, use of recombinant human erythropoietin, administration of iron and vitamins and delayed umbilical cord clamping have reduced the frequency of transfusions neonatal periods. The emergence of more stringent recommendations on indications for transfusion has been involved in this development. Various transformations and qualifications for red cell concentrates, platelet concentrates and fresh frozen plasma must be known to better adapt the blood products to newborn term and preterm according to their pathologies. Preparing pediatric units from a single donor for repeated transfusions reduces the allo-im...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4668485</comments>
            <pubDate>Thu, 24 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4668485</guid>        </item>
        <item>
            <title>[Chagas disease and blood transfusion: An emerging issue in non-endemic countries.]</title>
            <link>http://www.medworm.com/index.php?rid=4668470&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21440479%26dopt%3DAbstract</link>
            <description>Authors: Assal A, Corbi C
    Chagas disease or American human trypanosomiasis, is a parasitic disease due to Trypanosoma cruzi, which is endemic in Latin America. The parasite is transmitted by haematophagous vectors from reduviidae family. In some patients, the parasite is responsible for severe complications such as cardiac manifestations, gastrointestinal involvement and neurologic disease. Imported Chagas disease by immigration in non-endemic countries poses the threat of the infection transmission by blood transfusion. In order to prevent this risk, the French Blood Services (EFS) introduced systematic screening of at-risk blood donors for anti-T. cruzi antibodies, in May 2007. The concerned donors are people originating from an endemic area, donors with mothers originating from such...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4668470</comments>
            <pubDate>Thu, 24 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4668470</guid>        </item>
        <item>
            <title>[The safety of blood donors.]</title>
            <link>http://www.medworm.com/index.php?rid=4668467&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21440480%26dopt%3DAbstract</link>
            <description>Authors: Courchelle J, Baudry C, Bourboul MC, Coudurier N
    For a long time, safety has been patient-centred and taken for granted. Indeed, it needed a dramatic accident and the study of post-donation information for the question to be looked into again. However, under various statutory, organizational aspects and the professionalization of the staffs, safety has always accompanied the donor throughout its course of donation. Self-sufficiency is, certainly, the first mission of the Établissement Français du Sang: while we have to supply patients with sufficient blood products complying with quality criteria, we must not however forget the essential respect for the safety of the donor.
    PMID: 21440480 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4668467</comments>
            <pubDate>Thu, 24 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4668467</guid>        </item>
        <item>
            <title>[Transfusion for post-partum haemorrhage: What's new in 2011?]</title>
            <link>http://www.medworm.com/index.php?rid=4668487&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21420343%26dopt%3DAbstract</link>
            <description>Authors: Bonnet MP, Tesnière A, Mignon A
    Post-partum haemorrhage is the first cause of maternal death in France. In addition to the treatment of the cause, its treatment consists in the association of procoagulant drugs and blood transfusion. At risk situations requiring blood transfusion are well identified. However, they are not found in one third of the actually transfused patients. Therefore, for all deliveries, the medical team should be prepared to face a post-partum haemorrhage and to transfuse. As post-partum haemorrhage onset is most frequently acute, it is rare to be able to base the transfusion decision on biological parameters such as haemoglobin concentration and / or coagulation tests. The recently defined policy of early use of fresh frozen plasma in order to better con...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4668487</comments>
            <pubDate>Thu, 17 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4668487</guid>        </item>
        <item>
            <title>[Emergent viral threats in blood transfusion.]</title>
            <link>http://www.medworm.com/index.php?rid=4668488&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21414828%26dopt%3DAbstract</link>
            <description>Authors: Pozzetto B, Garraud O
    During the last 20 years, the safety of blood products increased dramatically with regard to the infectious risk and notably to that represented by retroviruses (HIV and HTLV) and hepatitis B and C viruses. The aim of this review is to identify the residual and emergent viral threats that could be responsible for the occurring of new contaminations in the receivers of blood products. Beside many other viruses (HHV-8, erythrovirus B19, hepatitis A and E viruses…), a special attention has been paid to emerging arbovirus diseases (West Nile virus infection, dengue, chikungunya) that threaten to occur in the French metropolitan area following the implantation in Europe of the mosquito Aedes albopictus, the main vector of dengue and chikungunya in temperate...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4668488</comments>
            <pubDate>Tue, 15 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4668488</guid>        </item>
        <item>
            <title>[In vitro platelet production.]</title>
            <link>http://www.medworm.com/index.php?rid=4607662&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21411355%26dopt%3DAbstract</link>
            <description>Authors: Dunois-Lardé C, Baruch D
    This review aims at presenting a state of the art on platelet functions, not only in well-characterized hemostasis and thrombosis, but also in various domains such as inflammation, immunity, angiogenesis, source of growth factors, metastasis and vascular remodelling. This multivalent phenotype of platelets suggests new potential applications of platelets. The second objective is to present new advances in platelet formation from megakaryocytes and direct platelet release, as initially shown by our group and more recently by others.
    PMID: 21411355 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607662</comments>
            <pubDate>Mon, 14 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607662</guid>        </item>
        <item>
            <title>[Computerization of hospital blood banks in France.]</title>
            <link>http://www.medworm.com/index.php?rid=4607661&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21411356%26dopt%3DAbstract</link>
            <description>Authors: Daurat G, Py JY
    In France, most blood products are delivered by the Établissement français du sang, directly to the recipients, and hospital blood banks deliver a minor part, but are independent from it. However that may be, hospital blood banks are hazardous activities regarding recipients, blood products, blood supply for the hospital and regional blood supply. Because of the high risk level, a computerized information system is compulsory for all hospital blood banks, except for those only devoted to vital emergency transfusion. On the field, integration of computerization in the different processes is very heterogeneous. So it has been decided to publish guidelines for computerizing hospital blood banks information systems and production management. They have been built ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607661</comments>
            <pubDate>Mon, 14 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607661</guid>        </item>
        <item>
            <title>[Organ transplantation and blood transfusion.]</title>
            <link>http://www.medworm.com/index.php?rid=4607665&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21398160%26dopt%3DAbstract</link>
            <description>Authors: Matignon M, Bonnefoy F, Lang P, Grimbert P
    Pretransplant blood transfusion remains a controversial subject and its history can summarize the last 40years of transplantation. Until 1971, transfusions were widely used in patients awaiting transplantation, especially due to the anemia induced by the chronic renal dysfunction. Then, a noxious effect of preformed anti-HLA antibodies on renal grafts survival was reported and pretransplant transfusions were stopped. Between 1972 and 1977, improvement of renal graft survival in patients who received pretransplant transfusions was noted. Therefore, from 1978 on, a systematic policy of pretransplant transfusions was adopted by almost all centres of transplantation. During the eighties, it was again abandoned for several reasons: absence...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607665</comments>
            <pubDate>Fri, 11 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607665</guid>        </item>
        <item>
            <title>[Access to blood donation of men who have sex with men and impact on the risk of HIV transmission by transfusion: International overview.]</title>
            <link>http://www.medworm.com/index.php?rid=4607664&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21398161%26dopt%3DAbstract</link>
            <description>Authors: Pillonel J, Semaille C
    As far back as 1983, in many countries, men who have sex with men were permanently excluded from blood donation because of their high risk of HIV infection. Since the implementation of HIV screening of blood donations in 1985, there has been a remarkable improvement in the viral safety of the blood supply due to improvements in donor selection and continuous progress in screening assays, including nucleic acid amplification testing. Despite, these improvements and the strong pressure of certain associations of the civil society, only few countries reduced the deferral duration for men who have sex with men. Studies that have assessed the impact of a modification of the permanent deferral measure on the HIV residual risk showed that a reduction in the def...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607664</comments>
            <pubDate>Fri, 11 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607664</guid>        </item>
        <item>
            <title>[Murine models in blood transfusion: Allo-immunization, hemolysis.]</title>
            <link>http://www.medworm.com/index.php?rid=4607663&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21398162%26dopt%3DAbstract</link>
            <description>Authors: Desmarets M, Noizat-Pirenne F
    Mice represent an animal model that can be easily manipulated. Mice have been used to model many human diseases. This review addresses murine models of immunity directed against red blood cell antigens as well as models of antibody and non-antibody mediated hemolysis. These models allow for a better understanding of the side effects of transfusion, such as red blood cell allo-immunization and post-transfusional hemolytic reactions. They also help explore strategies to treat and prevent these side effects in ways that would not be available using clinical research alone.
    PMID: 21398162 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607663</comments>
            <pubDate>Fri, 11 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607663</guid>        </item>
        <item>
            <title>[The methods used to collect hematopoietic stem cells.]</title>
            <link>http://www.medworm.com/index.php?rid=4607670&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21397542%26dopt%3DAbstract</link>
            <description>Authors: Hequet O
    The methods used to collect hematopoietic stem cells in their natural environment (bone marrow or cord blood) or in the peripheral blood after stimulation are well-defined and ruled both to ensure the donor security and perform a quality hematopoietic transplantation. Safety of the familial or non-familial donor must be ensured not only during the collection but also on a medium- or a long-term basis. The stem cells amount in a graft and its characterisation depend on the collection site of hematopoietic stem cells and on the technique used. The knowledge of conditions influencing these amounts allows optimising the hematopoietic stem cells collection while preventing conditions in which the donor safety could be decreased. The collection site also influences the coll...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607670</comments>
            <pubDate>Thu, 10 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607670</guid>        </item>
        <item>
            <title>[HLA and transfusion: New approaches with Luminex™ technology.]</title>
            <link>http://www.medworm.com/index.php?rid=4607669&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21397543%26dopt%3DAbstract</link>
            <description>Authors: Giannoli C, Nguyen TK, Dubois V
    The major histocompatibility complex is a multigenic system highly polymorphic coding for human leukocyte antigen (HLA) molecules, which are the strongest antigens for immune response and play a major role in allograft rejection. Class I antigens are expressed on almost all nucleated cells and platelets, whereas HLA class II antigens are mostly on antigen presenting cells. During transfusion, anti-HLA antibodies can induce transfusion incidents like fever, transfusion-related acute lung injury TRALI and refractoriness to the platelets transfusion. Identification of HLA class I antibodies is very important to find HLA compatible platelets concentrates. Since the end of 1960s, the complement-dependant microlymphocytotoxicity assay has been the sta...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607669</comments>
            <pubDate>Thu, 10 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607669</guid>        </item>
        <item>
            <title>[Ten years of nucleic acid testing: Lessons and prospects.]</title>
            <link>http://www.medworm.com/index.php?rid=4607668&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21397544%26dopt%3DAbstract</link>
            <description>Authors: Morel P
    Nucleic acid testing has been routinely performed in all blood donations in France since July 1st 2001. This is the story of a controversial decision. &quot;The unacceptable HIV risk&quot; in the context of the early 2000s influenced the decision. The results achieved over these past 10years are analyzed given the expected progress of this new screening tool for infectious agents in transfusion. They confirm the relevance of models used by experts in 2000. Out of 22.3 million donations over the period (2001-2009), 22 donations have been rejected because of nucleic acid testing positive for hepatitis C virus (n=11) and human immunodeficiency virus (n=11). Nucleic acid testing has contributed to improve the functioning of the transfusion chain activities in order to ensure the ava...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607668</comments>
            <pubDate>Thu, 10 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607668</guid>        </item>
        <item>
            <title>[Use of adipose tissue in regenerative medicine.]</title>
            <link>http://www.medworm.com/index.php?rid=4607667&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21397545%26dopt%3DAbstract</link>
            <description>Authors: Casteilla L, Planat-Benard V, Bourin P, Laharrague P, Cousin B
    Adipose tissue is abundant and well known for its involvement in obesity and associated metabolic disorders. Its uses in regenerative medicine recently attracted many investigators, as large amounts of this tissue can be easily obtained using liposuction and it contains several populations of immature cells. The largest pool of such cells corresponds to immature stromal cells, called adipose-derived stromal cells (ADSCs). These cells are purified after proteolytic digestion of adipose tissue and selection by an adherent step. ADSCs display many common features with mesenchymal stem cells derived from bone marrow, including paracrine activity, but with some specific features, among which a greater angiogenic potenti...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607667</comments>
            <pubDate>Thu, 10 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607667</guid>        </item>
        <item>
            <title>[Management of feto-maternal red cell allo-immunizations.]</title>
            <link>http://www.medworm.com/index.php?rid=4607666&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21397546%26dopt%3DAbstract</link>
            <description>The objective of management strategies of feto-maternal alloimmunization is to detect and monitor maternal alloimmunization and to appreciate the effects on the fetus or the newborn. Since a few years, some new non-invasive techniques of surveillance are used, for instance fetal RHD genotyping on maternal plasma and evaluation of fetal anaemia through velocimetry measurement of the blood flow in the middle cerebral artery. The need for a careful postnatal surveillance has to be emphasized due to the neonatal anaemia, which can be prolonged, and to the resurgence of cases of severe neonatal icteruses recently reported by the Académie de Médecine. The policy of prevention of anti-RH1 alloimmunization should also benefit from the evolution of biological techniques by allowing an improved ta...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607666</comments>
            <pubDate>Thu, 10 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607666</guid>        </item>
        <item>
            <title>[Serum transferrin receptor in the assessment of iron status.]</title>
            <link>http://www.medworm.com/index.php?rid=4607671&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21376650%26dopt%3DAbstract</link>
            <description>This report is devoted to the soluble transferrin receptors. We analyzed the comparison between ferritin, soluble transferrin receptors and C reactive protein. The soluble receptor measurement represents a significal advance in assessment of iron status, especially in the diagnosis of iron deficiency associated with inflammation, and in the evaluation of red blood mass during erythroid hyperplasias.
    PMID: 21376650 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607671</comments>
            <pubDate>Wed, 02 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607671</guid>        </item>
        <item>
            <title>[Mesenchymal stromal cells: Biological properties and clinical prospects.]</title>
            <link>http://www.medworm.com/index.php?rid=4545495&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21367635%26dopt%3DAbstract</link>
            <description>Authors: Roux S, Leotot J, Chevallier N, Bierling P, Rouard H
    Mesenchymal stromal cells are defined as non-hematopoietic progenitors caracterised by their adherence to plastic in culture, their expression of non-specific markers and their differentiation potential into cells of mesodermic lineage. Resident in numerous tissues, mesenchymal stromal cells are now available from several sources, including both adult and foetal tissues. After their administration, mesenchymal stromal cells preferentially migrate to injured tissues. Mesenchymal stromal cells have therapeutic effects in numerous animal models of tissu injury by a mecanism not yet clearly understood. Mecanisms likely involved in repair can be the production of paracrine, anti-inflammatory and anti-apoptotic factors, as well as...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4545495</comments>
            <pubDate>Mon, 28 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4545495</guid>        </item>
        <item>
            <title>[Transfusion transmitted bacterial infectious (TTBI) with blood component accountability score 2: Retrospective analysis of the French e-fit database 2000-2007.]</title>
            <link>http://www.medworm.com/index.php?rid=4490230&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21310643%26dopt%3DAbstract</link>
            <description>CONCLUSION: The improvement measures taken as part of the French haemovigilance declaration framework allowed to perfect the data quality of transfusion transmitted bacterial infection. Progresses are still to be made to improve clinical and biological declaration, in order to precise the accountability of a blood component in the occurrence of an adverse transfusion transmitted bacterial infection effect. Tracking transfusion transmitted bacterial infection notifications by a group of experts at the national level is still recommended.
    PMID: 21310643 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4490230</comments>
            <pubDate>Tue, 08 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4490230</guid>        </item>
        <item>
            <title>[Mortality and morbidity conference: A tool for quality and safety of care continuous improvement.]</title>
            <link>http://www.medworm.com/index.php?rid=4490231&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21306932%26dopt%3DAbstract</link>
            <description>The objective of this work was to describe a MMC by presenting a case report. CASE REPORT: A 16-year old man suffering from chronic anaemia had to be transfused with two units of red blood cells in an outpatient unit. Although the transfusion went well for the first unit, the patient presented haemolysis during the transfusion of the second unit because the nurse administered the wrong unit. The incident was analysed during a mortality and morbidity conference with the attendance of the hemovigilance local correspondent. Immediate causes of the event were the failure to respect the transfusion procedure: in advance compatibility testing, failure to check the patient and blood component identification just before the transfusion. Factors contributing to the event were the deviation of trans...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4490231</comments>
            <pubDate>Mon, 07 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4490231</guid>        </item>
        <item>
            <title>[Evaluation of continuous education in transfusion for professionals in medical blood banks.]</title>
            <link>http://www.medworm.com/index.php?rid=4357088&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21237687%26dopt%3DAbstract</link>
            <description>CONCLUSION: At the end of its third year of existence, the 35hours education programme permitted to achieve a better level of training for all the staffs and the evolution towards an on-site continuing education format seems to better correspond to the personnel's expectations.
    PMID: 21237687 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4357088</comments>
            <pubDate>Thu, 13 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4357088</guid>        </item>
        <item>
            <title>[Fetal RHD genotyping by PCR using plasma from D negative pregnant women.]</title>
            <link>http://www.medworm.com/index.php?rid=4357098&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21190884%26dopt%3DAbstract</link>
            <description>CONCLUSION: These results demonstrate de feasibility of fetal RHD genotyping by conventional PCR in D negative pregnant women of Moroccan origin.
    PMID: 21190884 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4357098</comments>
            <pubDate>Mon, 27 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4357098</guid>        </item>
        <item>
            <title>[Transfusion and postpartum haemorrhage.]</title>
            <link>http://www.medworm.com/index.php?rid=4159554&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21067949%26dopt%3DAbstract</link>
            <description>Authors: Ducloy-Bouthors AS, Blondé-Zoonekynd E, Jaillette E, Richart P, Barre-Drouard C, Wibaut B, Ducloy JC, Sicot J, Depret-Mosser S, Godier A, Susen S
    Postpartum haemorrhage is the leading cause of maternal death in France and worldwide. Guidelines help to conduct a timed management and to reduce maternal morbidity and mortality. Rescue and surgical care, transfusion and monitoring have to be previously organized.
    PMID: 21067949 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4159554</comments>
            <pubDate>Mon, 08 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4159554</guid>        </item>
        <item>
            <title>[Immuno-haematology and blood bank inventory and issue management.]</title>
            <link>http://www.medworm.com/index.php?rid=4159553&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21067950%26dopt%3DAbstract</link>
            <description>Authors: Madre F, Benoist F, Chandesris C, Nicola N
    Blood bank management must ensure the correct blood product issuance in the right time. For this purpose, patient clinical and immuno-haematological data have to be taken into consideration. Inventory composition, by blood group and phenotype, blood product providing possibilities and transport delays are determining factors. Finally, a good management relies also on the use of consensually written procedures and the monitoring of pertinent indicators.
    PMID: 21067950 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4159553</comments>
            <pubDate>Mon, 08 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4159553</guid>        </item>
        <item>
            <title>Anemia, fatigue and aging.</title>
            <link>http://www.medworm.com/index.php?rid=4159552&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21067951%26dopt%3DAbstract</link>
            <description>This article reviews the causes and the consequences of anemia in the older individual. The most common causes include chronic inflammation that is a typical manifestation of aging, iron deficiency that may be due to chronic hemorrhage, malabsorption and Helicobacter pylori infection, cobalamin deficiency from malabsorption and renal insufficiency. Other causes of anemia whose prevalence is not well established include myelodysplasia, copper deficiency, hypothyroidism, and sarcopenia. Anemia is associated with increased risk of mortality, functional dependence, dementia, falls, and chemotherapy-related toxicity. When correcting the anemia of older cancer patients one should remember that the erythropoietic stimulating agents (ESA) may stimulate cancer growth and cause thrombosis. These pro...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4159552</comments>
            <pubDate>Mon, 08 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4159552</guid>        </item>
        <item>
            <title>[International databases: Usefulness and limitations in hemovigilance.]</title>
            <link>http://www.medworm.com/index.php?rid=4159556&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21055991%26dopt%3DAbstract</link>
            <description>Authors: Wiersum-Osselton JC
    A number of international databases are well-known and useful tools for professionals in blood transfusion. The advent of national hemovigilance registries and an international focus on transfusion practice and transfusion safety has led individuals and organisations to collect and compare data. This has led to the development of internationally useful indicators, for instance figures for the numbers of red cell products transfused per 1000 in the population. An international database of hemovigilance data (surveillance database for transfusion associated adverse reactions and events [STARE]) is currently being developed by the International Hemovigilance Network. In the pilot phase, it is seen that differences exist between the rates of adverse reactions a...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4159556</comments>
            <pubDate>Wed, 03 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4159556</guid>        </item>
        <item>
            <title>[Suitability of red blood cell transfusion: A multicenter study.]</title>
            <link>http://www.medworm.com/index.php?rid=4159555&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21055992%26dopt%3DAbstract</link>
            <description>In this study, the trigger haemoglobin concentration is &quot;restrictive&quot;, but the target haemoglobin concentration is &quot;liberal&quot; with a high-discharge haemoglobin concentration. Inappropriate RBC transfusions are mainly due to over-transfusion.
    PMID: 21055992 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4159555</comments>
            <pubDate>Wed, 03 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4159555</guid>        </item>
        <item>
            <title>[Health alert management and emerging risk.]</title>
            <link>http://www.medworm.com/index.php?rid=4141426&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051258%26dopt%3DAbstract</link>
            <description>Authors: Pillonel J
    Following health crisis that have occurred in the nineties (contaminated blood, mad cow, asbestos, etc.) and more recently those generated by the heat wave in 2003 or by emerging infectious pathogens (SARS, West Nile, Chikungunya, H5N1, H1N1…), a real health vigilance system has been progressively developed in France. After a brief historical overview of the health alert system, this article will give the guiding principles of its current organization in France and will present two examples of recent health alerts (Chikungunya in the Reunion Island in 2005-2006 and hepatitis A outbreak in the Côtes-d'Armor in August 2007), that have needed the implementation of preventive measures regarding the blood donor selection. These two examples have shown that the positio...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141426</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141426</guid>        </item>
        <item>
            <title>[Out-of-hospital blood transfusion by emergency medical services.]</title>
            <link>http://www.medworm.com/index.php?rid=4141425&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051259%26dopt%3DAbstract</link>
            <description>Authors: Fournier M, Chenaitia I
    The indications for out-of-hospital blood transfusion by emergency medical services (EMS) are relatively rare (0.2 to 1% of interventions). The guidelines and the law about transfusion seem to be a hindrance for out-of-hospital blood transfusion. In prehospital settings, the main concern is the quick supply of blood products, while for interhospital transports the priority is to ensure haemovigilance, thanks to transfusion records. Blood transfusion into mobile intensive care units have to be conform with rules of good practice and guidelines, but it is necessary to consider the specific sanitary conditions in prehospital emergency medicine, which often cause a delay to perform it and this delay must be known by emergency physicians. The writing of a bl...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141425</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141425</guid>        </item>
        <item>
            <title>[Post-transfusion pulmonary oedema: The French hemovigilance network classification method.]</title>
            <link>http://www.medworm.com/index.php?rid=4141424&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051260%26dopt%3DAbstract</link>
            <description>Authors: Ozier Y, Renaudier P, Caldani C, Aguilon P, Canivet N, Fabrigli P, Mertes PM, Muller JY, Rebibo D, Tazerout M, Trophilme C, Willaert B, Carlier M
    Pulmonary oedema after transfusion of blood products may be hydrostatic (transfusion-associated circulatory overload [taco]) or exsudative (transfusion-related acute lung injury [trali]). Both conditions have been recognized as major hazards to transfusion recipients. Risk characterization is necessary to improve safety and to monitor trends in the national blood transfusion system. A collaborative multidisciplinary working group of the French National Hemovigilance Committee has proposed an analysis framework for case definitions and classification. The method relies on internationally used definitions and is adapted to the codifica...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141424</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141424</guid>        </item>
        <item>
            <title>[The management of post donation information: A fundamental element of blood safety.]</title>
            <link>http://www.medworm.com/index.php?rid=4141423&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051261%26dopt%3DAbstract</link>
            <description>Authors: Hervé I, Simonet M, Rebibo D, Leconte Des Floris MF, Taouqi-Le Cann M, Jbilou S, Brunet A
    Post donation information management is a fundamental axis of haemovigilance in terms of blood safety. It requires an organization ensuring a permanent reactivity, a good sensitization of French National Blood Service professionals and needs also a strong awareness of blood donors. Previous identification of stakeholders to warn during these kinds of alerts is essential to avoid the use of any blood product presenting a potential risk. The recent implementation of a consensual internal document aims to target the reinforcement of a homogeneous decision-making process, combining blood product self-sufficiency and above all recipient safety.
    PMID: 21051261 [PubMed - as supplied by publ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141423</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141423</guid>        </item>
        <item>
            <title>[Transfusion in palliative care in child with malignant disease.]</title>
            <link>http://www.medworm.com/index.php?rid=4141422&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051262%26dopt%3DAbstract</link>
            <description>Authors: Munzer M
    Transfusion occupies an important part of medical care in the palliative phase of paediatric malignancies with major bone marrow involvement. The aim of transfusion is to improve the quality of life. Fatigue is a frequent symptom in palliative phase, in children as well as in adults; anaemia is one of the responsible factor. Transfusion of red blood cells may contribute to the improvement this symptom. Specific pediatric recommendations are lacking, but studies in adults and clinical experience allow thinking that we should take into account the evaluation of this fatigue, more than a threshold value of haemoglobin. Platelets transfusion indication depends on the preserved activity and mobility of the child. The possibility of transfusion at home should reduce the con...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141422</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141422</guid>        </item>
        <item>
            <title>[French European military haemovigilance guidelines.]</title>
            <link>http://www.medworm.com/index.php?rid=4141421&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051263%26dopt%3DAbstract</link>
            <description>Authors: Sailliol A, Clavier B, Cap A, Ausset S
    European military transfusion services follow operational guidelines established by their respective national health systems and conform with European Union directives and NATO standards as applicable to member countries. Certain features are common to all of these standards, especially the pre-selection of volunteer, almost exclusively unpaid donors. NATO requirements are very close to European guidelines, with the exception that NATO permits the use of blood products collected in emergency conditions in theater when circumstances allow no better option. Blood product traceability exists for every country but is not always centralized or computerized. Serious adverse event reporting relies on national haemovigilance networks. Military co...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141421</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141421</guid>        </item>
        <item>
            <title>[Blood in art, art in blood.]</title>
            <link>http://www.medworm.com/index.php?rid=4141420&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051264%26dopt%3DAbstract</link>
            <description>Authors: Danic B, Lefrère JJ
    In the different forms of art developed by Humanity over the centuries, artists have at times chosen themes from the world of medicine or health, such as blood donation or transfusion. In order to illustrate this, we have looked at three artistic domains: painting, movies and body art.
    PMID: 21051264 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141420</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141420</guid>        </item>
        <item>
            <title>[From clinical practice evaluation programme to relevant transfusions.]</title>
            <link>http://www.medworm.com/index.php?rid=4141419&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051265%26dopt%3DAbstract</link>
            <description>Authors: Devie I
    Clinical practice evaluation programme is now a mandatory process for healthcare institutions. Integrative part of the certification procedures conducted by the French National Health Agency (Haute Autorité de Santé [HAS]), it has became a new major approach to improve both the quality and the safety of healthcare. It concerns also transfusional practices.
    PMID: 21051265 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141419</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141419</guid>        </item>
        <item>
            <title>[Hospital blood bank: Information system and immuno-hematology.]</title>
            <link>http://www.medworm.com/index.php?rid=4141418&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051266%26dopt%3DAbstract</link>
            <description>Authors: Vaquier C, Caldani C
    Due to regulations, hospital blood banks have to equip them with a computer-based information system. This system facilitates the management of the blood bank and ensures the safety of the storage, issuing and traceability of the blood and blood components. It permits to create a medical file for each transfused patient, which contains the characteristics of the blood components transfused and the immunohematological status of the patient, received by electronic data interchange from the blood establishment. Thus, from the assistance to the prescription of blood transfusion to the issuing and traceability of the blood components, the computer-based information system is the guarantee of the transfusion security in a hospital blood bank.
    PMID: 21051266 ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141418</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141418</guid>        </item>
        <item>
            <title>[Recipients adverse reactions: Guidance supports.]</title>
            <link>http://www.medworm.com/index.php?rid=4141417&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051267%26dopt%3DAbstract</link>
            <description>Authors: Bazin A
    Since 1994, adverse effects of transfusion transmitted to the French haemovigilance network are registered on &quot;e-fit&quot;, the database of the French agency for the safety of health products (Afssaps). In order to improve their analysis, guidance supports have been made by Afssaps working groups. Each support deals with a blood transfusion side effect and is composed of five parts including pathophysiological mechanisms, diagnostic criteria, management recommendations, etiologic investigations and rules of filing the notification form on e-fit. The major characteristics of sheets published or soon-to-be published are presented: transfusion-related acute lung injury, transfusion-transmitted bacterial infection, non-haemolytic febrile reaction, allergic reaction, transfusion...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141417</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141417</guid>        </item>
        <item>
            <title>[Blood transfusion in emergency settings: French military health service experience.]</title>
            <link>http://www.medworm.com/index.php?rid=4141416&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051268%26dopt%3DAbstract</link>
            <description>Authors: Sailliol A, Ausset S, Peytel E
    Blood transfusion is required in a number of emergency settings and the French military health service (FMHS) has issued specific guidelines for the treatment of war casualties. These guidelines take into account European standards and laws, NATO standards, and also public sentiment regarding transfusion. These guidelines reflect a determination to control the process and to avoid the improvisation frequently associated with wartime transfusion. The evolution in warfare (terrorism and bombing more frequent than gunshot) and the wide use of body armor have deeply changed the clinical presentation of war injuries. These now involve the extremities in 80% of cases, with extensive tissue damage and heavy blood loss. The FMHS recommends that war casua...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141416</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141416</guid>        </item>
        <item>
            <title>[Home blood transfusion.]</title>
            <link>http://www.medworm.com/index.php?rid=4141415&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051269%26dopt%3DAbstract</link>
            <description>We report our experience of 3years: a protocol was established to do home blood transfusions by trained transfusion nurses from the HAD. Six patients were eligible for transfusion at home but only three of them could be treated at home. Moreover, since late 2009, the Nursing Department no longer allows this practice for legal reasons. At the same time, a questionnaire was sent to 224 HAD to find out about their practice on the subject. DISCUSSION: In the light of practices in different countries, earnings for the quality of life of the patient, lack of space in hospitals and the aging population, it seems essential to change the law to permit a rational transfusion, thoughtful, safe for the patient at home and for caregivers who are involved.
    PMID: 21051269 [PubMed - as supplied by pu...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141415</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141415</guid>        </item>
        <item>
            <title>[Serious adverse effects of blood collection.]</title>
            <link>http://www.medworm.com/index.php?rid=4141414&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21051270%26dopt%3DAbstract</link>
            <description>This article focuses on the organization of the French notification system, and the management of the main side effects known and reported.
    PMID: 21051270 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141414</comments>
            <pubDate>Tue, 02 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141414</guid>        </item>
        <item>
            <title>[European regulation on blood and blood components.]</title>
            <link>http://www.medworm.com/index.php?rid=4141432&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21050786%26dopt%3DAbstract</link>
            <description>Authors: Sandid I
    The European regulation on blood and blood components is declined in four directives: the Directive 2002/98/EC known as &quot;mother Directive&quot; and three directives called &quot;daughter Directives&quot; 2004/33/EC, 2005/61/EC and 2005/62/EC. It constitutes a common basis of provisions of quality and safety of blood in the European Union (EU), thus guaranteeing this safety and this quality with the whole of the citizens circulating in Member States of the Union. It cannot prevent a Member State for maintaining or introducing more stringent protective measures. It encourages the anonymous, voluntary and unpaid blood donations. It envisages many provisions for the prospective blood donor eligibility, the blood collection, the testing, processing, storage, transport, distribution and i...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141432</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141432</guid>        </item>
        <item>
            <title>[Immunological blood transfusion safety and selection of red blood cells issued from hospital blood banks.]</title>
            <link>http://www.medworm.com/index.php?rid=4141430&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21050787%26dopt%3DAbstract</link>
            <description>Authors: Py JY
    Allogeneic red blood cells transfusion is always an immunological challenge and the choice of the blood products is crucial for the patient safety. But this choice may be hampered by the quality or the quantity of the available supply. In the end, the lack of transfusion may be more harmful than transfusion. The balance between patients' needs and blood centres supplying is always delicate. The conditions are not the same for all blood groups. Things are easier for the KEL1 phenotype, where the supply must ensure only 92.5% of KEL: -1 red blood cells instead of the 91% expected. More complicated is the situation for group O red blood cells with 47 versus 43%. But the major problem concerns RH: -1 red blood cells, for which the needs reach 20.1 versus 15%. These challenge...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141430</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141430</guid>        </item>
        <item>
            <title>[Patient safety and root cause analysis.]</title>
            <link>http://www.medworm.com/index.php?rid=4141429&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21050788%26dopt%3DAbstract</link>
            <description>Authors: Auroy Y, Andreu G, Aullen JP, Benhamou D, Caldani C, Canivet N, de Lardemelle C, Roure FD, François A, Gruber M, Sandid I, Linget C, Loulière B, Perrin M, Rebibo D, Richomme X, Tinard X
    Safety in the field of transfusion medicine has greatly improved in France. The risk of viral transmission has decreased by a factor greater than 1500 within the last 20 years. In comparison, the risk related to ABO error has decreased only by half. The reporting of critical incidents, which occur at any step of the transfusion procedure is now mandatory in France and is subject to an in-depth analysis, using methods close to that used in aviation safety. The goal of these analyses is to better understand human factors in order to implement more adequate prevention measures.
    PMID: 21050...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141429</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141429</guid>        </item>
        <item>
            <title>[Oncology blood transfusion and quality of life: Review.]</title>
            <link>http://www.medworm.com/index.php?rid=4141428&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21050789%26dopt%3DAbstract</link>
            <description>Authors: Poirier AL, Commer JM, Kwiatkowski F, Mercier M, Bonnetain F
    Blood transfusion's repercussions on quality of life are less well studied in cancer research, and rarer in palliative situation. It is necessary to look for studies dealing with anaemia to estimate its effects. In curative palliative situation, the situation is similar to that of curative stage patients. It is necessary landing quickly for anaemia to assure the patient's quality of life. Blood transfusion and more recently erythropoïesis-stimulating agents are effective treatments. In advanced palliative stage, transfusion improves symptoms (weakness and dyspnoea bound anaemia) and the patients' well being. The treatment choice must be individual and has to follow an ethical behaviour in respect with the legislatio...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141428</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141428</guid>        </item>
        <item>
            <title>[Reporting and notification of transfusion serious adverse events in France.]</title>
            <link>http://www.medworm.com/index.php?rid=4141427&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21050790%26dopt%3DAbstract</link>
            <description>Authors: Daurat G
    Surveillance of serious adverse events in transfusion has recently been enforced in all European Union member states, and in France in 2007. This is an important expansion of the field of haemovigilance towards risk management in transfusion from donor selection to recipients follow up. Participation in this notification system is mandatory for all health professionals. They have to report immediately all serious adverse events to the haemovigilance officer of their hospital or transfusion centre. In accordance with a national procedure, the latter has to notify all serious adverse events to regional and national competent authorities using a web-based application. They also have to perform a root case analysis and propose corrective measures. However, as the definiti...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4141427</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4141427</guid>        </item>
        <item>
            <title>[Genotyping of 21,000 blood donors in Quebec and RHD analysis.]</title>
            <link>http://www.medworm.com/index.php?rid=4098890&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20965765%26dopt%3DAbstract</link>
            <description>CONCLUSION: Thanks to this project, Héma-Québec is able to answer increasing demands for compatible blood more rapidly. The organisation has also demonstrated the security of its D negative inventory.
    PMID: 20965765 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098890</comments>
            <pubDate>Mon, 18 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098890</guid>        </item>
        <item>
            <title>[Results of partial transfusion exchange in 42 homozygous sickle cell patients at University hospital of Brazzaville.]</title>
            <link>http://www.medworm.com/index.php?rid=4098889&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20965766%26dopt%3DAbstract</link>
            <description>This study illustrates the benefit and the limitations of the transfusion exchange during sickle cell disease in sub-Saharan Africa.
    PMID: 20965766 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098889</comments>
            <pubDate>Mon, 18 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098889</guid>        </item>
        <item>
            <title>[Characteristics of transfusion recipients in Bordeaux University Hospital. A descriptive study using hospital claims and haemovigilance system databases.]</title>
            <link>http://www.medworm.com/index.php?rid=4098888&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20965767%26dopt%3DAbstract</link>
            <description>CONCLUSION: This study provided a clinical profile of the transfused patients. Data collected could be used to plan blood collection and to define objectives and resources of healthcare establishments.
    PMID: 20965767 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098888</comments>
            <pubDate>Mon, 18 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098888</guid>        </item>
        <item>
            <title>[Appearance of anti-red blood cell antibodies in 80years old and over transfused patients: Result of 3years haemovigilance survey.]</title>
            <link>http://www.medworm.com/index.php?rid=4098895&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20961785%26dopt%3DAbstract</link>
            <description>CONCLUSION: In the transfused patient population aged 80 and over, RBC Ab are common and in most cases are due to RBC transfusions. On the contrary, pretransfusion RBC Ab are not frequent.
    PMID: 20961785 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098895</comments>
            <pubDate>Sun, 17 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098895</guid>        </item>
        <item>
            <title>Antenatal Rh prophylaxis is unnecessary for &quot;Asia type&quot; DEL women.</title>
            <link>http://www.medworm.com/index.php?rid=4098894&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20961786%26dopt%3DAbstract</link>
            <description>CONCLUSION: The data indicate that the &quot;Asia type&quot; DEL variant does not appear at risk of alloimmunization to the D antigen. It strongly suggests that the antenatal Rh immune globulin prophylaxis is unnecessary for DEL women. Furthermore, it implicates that the &quot;Asia type&quot; DEL may be deemed Rh-positive safely for clinical transfusion therapy.
    PMID: 20961786 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098894</comments>
            <pubDate>Sun, 17 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098894</guid>        </item>
        <item>
            <title>[Occurrence of severe, persistent thrombocytopenia following allogeneic bone marrow transplantation, attributable to anti-HPA-1 allo-immunisation of the host.]</title>
            <link>http://www.medworm.com/index.php?rid=4098893&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20961787%26dopt%3DAbstract</link>
            <description>Authors: Parissiadis A, Bilger K, Laplace A, Berceanu A, Schwebel M, Froelich N, Cazenave JP, Hanau D, Tourne S, Lioure B
    A 56 year-old, multiparous woman suffering from a myeloproliferative syndrome, who had received multiple red blood cell and platelet transfusions, was the recipient of an allograft of peripheral blood stem cells derived from her HLA-A, B, DR, DQ and DP and ABO identical sister, following myeloablative conditioning. The persistence of severe, isolated thrombopenia resistant to platelet transfusions led to the discovery of anti-HLA class I allo-immunisation. As HLA compatible platelet transfusions did not result in satisfactory platelet increments, we then discovered the simultaneous presence of anti-HPA-1a allo-immunisation. Genotyping of the HPA-1 systems of the pat...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098893</comments>
            <pubDate>Sun, 17 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098893</guid>        </item>
        <item>
            <title>Multiple transfusions for sickle cell disease in the Democratic Republic of Congo: The importance of the hepatitis C virus.</title>
            <link>http://www.medworm.com/index.php?rid=4098892&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20961788%26dopt%3DAbstract</link>
            <description>CONCLUSION: HCV testing should be a priority. The rhesus (Rh) phenotype, mainly the RhD antigen and the Kell antigen should be assessed in SCD patients. Further extended phenotyping and deleucocytation should not be considered as priorities.
    PMID: 20961788 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098892</comments>
            <pubDate>Sun, 17 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098892</guid>        </item>
        <item>
            <title>[Frequency of red blood cell alloimmunization in polytransfused patients at the university teaching hospital of Point G, Bamako, Mali.]</title>
            <link>http://www.medworm.com/index.php?rid=4098891&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20961789%26dopt%3DAbstract</link>
            <description>Authors: Baby M, Fongoro S, Cissé M, Gakou Y, Bathily M, Dembélé AK, Maïga MK, Tounkara A, Diallo DA
    This prospective study conducted within 9 months period aimed to determine the frequency of red cell alloimmunization among polytransfused patients of the medical Hematology and oncology ward, and the unit of hemodialysis of the Nephrology ward at the Point-G hospital. Irregular red blood cell antibody screening and identification were performed by gel-filtration method using indirect antiglobulin test and enzymatic treated cells. We did not use saline medium. A total of 78 patients were included in this study. The mean age of the patients was 36.78±14.73 years (range: 11 and 77 years). The sex ratio was of 1.11 in favour of the women. The mean blood units transfused were 12.21...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098891</comments>
            <pubDate>Sun, 17 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098891</guid>        </item>
        <item>
            <title>[First French transfusions (1667-1668).]</title>
            <link>http://www.medworm.com/index.php?rid=4067108&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20926327%26dopt%3DAbstract</link>
            <description>Authors: Jaulin P, Lefrère JJ
    The pioneers of blood transfusion first appeared in the 17th century, mainly in France and England, through animal experimentation, followed by some attempts in the healthy or sick. In France, the names of Dom Robert and Jean-Baptiste Denis belong to the beginning of the adventure of transfusion. Transfusions were then made with a total lack of knowledge of immunological danger. Following the death of a transfused patient, a death most likely related to acute intravascular hemolysis, the practice of transfusion was prohibited, on both sides of the Channel, by decision of Parliament.
    PMID: 20926327 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4067108</comments>
            <pubDate>Sun, 03 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4067108</guid>        </item>
        <item>
            <title>Evolution of the spectrin-based membrane skeleton.</title>
            <link>http://www.medworm.com/index.php?rid=3845578&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20688550%26dopt%3DAbstract</link>
            <description>Authors: Baines AJ
    A group of four proteins - spectrin, ankyrin, 4.1 and adducin - evolved with the metazoa. These membrane-cytoskeletal proteins cross-link actin on the cytoplasmic face of plasma membranes and link a variety of transmembrane proteins to the cytoskeleton. In this paper, the evolution of these proteins is analysed. Genomics indicate that spectrin was the first to appear, since the genome of the choanoflagellate Monosiga brevicolis contains genes for alpha, beta and betaH spectrin. This organism represents a lineage of free-living and colonial protists from which the metazoa are considered to have diverged. This indicates that spectrin emerged in evolution before the animals. Simple animals such as the placozoan Trichoplax adherens also contain recognizable precursors of...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3845578</comments>
            <pubDate>Mon, 02 Aug 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3845578</guid>        </item>
        <item>
            <title>A transcriptome-based examination of blood group expression.</title>
            <link>http://www.medworm.com/index.php?rid=3828204&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20685146%26dopt%3DAbstract</link>
            <description>Authors: Noh SJ, Lee YT, Byrnes C, Miller JL
    Over the last two decades, red cell biologists witnessed a vast expansion of genetic-based information pertaining to blood group antigens and their carrier molecules. Genetic progress has led to a better comprehension of the associated antigens. To assist with studies concerning the integrated regulation and function of blood groups, transcript levels for each of the 36 associated genes were studied. Profiles using mRNA from directly sampled reticulocytes and cultured primary erythroblasts are summarized in this report. Transcriptome profiles suggest a highly regulated pattern of blood group gene expression during erythroid differentiation and ontogeny. Approximately one-third of the blood group carrier genes are transcribed in an erythroid-...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3828204</comments>
            <pubDate>Sun, 01 Aug 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3828204</guid>        </item>
        <item>
            <title>Metabolomic analysis of normal and sickle cell erythrocytes.</title>
            <link>http://www.medworm.com/index.php?rid=3813977&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674434%26dopt%3DAbstract</link>
            <description>Authors: Darghouth D, Koehl B, Junot C, RomÃ©o PH
    Metabolic signatures of specialized circulating hematopoietic cells in physiological or human hematological diseases start to be described. We use a simple and highly reproductive extraction method of erythrocytes metabolites coupled with a liquid chromatography-mass spectrometry based metabolites profiling method to determine metabolomes of normal and sickle cell erythrocytes. Sickle cell erythrocytes and normal erythrocytes metabolomes display major differences in glycolysis, in glutathione, in ascorbate metabolisms and in metabolites associated to membranes turnover. In addition, the amounts of metabolites derived from urea cycle and NO metabolism that partly take place within erythrocyte were different between normal and sickle ce...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813977</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813977</guid>        </item>
        <item>
            <title>Red cell membrane and malaria.</title>
            <link>http://www.medworm.com/index.php?rid=3813976&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674435%26dopt%3DAbstract</link>
            <description>Authors: An X, Mohandas N
    Malaria is the most serious and widespread parasitic disease of humans, with up to 500 million people being infected each year with malaria parasites and a million individuals, predominantly infants and young children, dying as a consequence of the infection. During intra-erythrocytic life cycle of 48h, over 400 proteins produced by parasites are exported into the red cell cytoplasm and a number of these proteins interact with membrane skeleton. Significant progress is being made in identifying the binding domains in both parasite proteins and red cell proteins that mediate protein-protein interactions. These various parasite-red cell protein interactions are responsible for striking structural and morphological changes in the infected red cell including loss ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813976</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813976</guid>        </item>
        <item>
            <title>[Quality and safety about hemapheresis practicing: From a self-evaluation of medical practices to a systematic risk management process.]</title>
            <link>http://www.medworm.com/index.php?rid=3813970&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674436%26dopt%3DAbstract</link>
            <description>Authors: LefÃ¨vre PA, Audat F, Giraud C, Roussel P
    Hemapheresis is made up of a set of essential methods for modern medical practices. Applicated to donors, they allow production of labile blood products as well as raw material for plasma products industrial manufacturing; applicated to patients, they are indispensable for the treatment of many pathologies. Conditions for their implementation are very variable according to the teams who have few tools at their disposal to access, standardize and make reliable their activity. Therefore, an approach has been initiated by the Institut National de la Transfusion Sanguine and the Hemapheresis French Society to develop a guide which primary goal is to help teams evaluate themselves in different areas of their responsabilities. The generali...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813970</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813970</guid>        </item>
        <item>
            <title>Transport mechanisms in the ammonium transporter family.</title>
            <link>http://www.medworm.com/index.php?rid=3813967&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674437%26dopt%3DAbstract</link>
            <description>Authors: Lamoureux G, Javelle A, Baday S, Wang S, BernÃ¨che S
    Ammonium transport is mediated by membrane proteins of the ubiquitous Amt/Rh family. Despite the availability of different X-ray structures that provide many insights on the ammonium permeation process, the molecular details of its mechanism remain controversial. The X-ray structures have revealed that the pore of the Amt and Rh proteins is characterized by a hydrophobic portion about 12A long in which electronic density was observed in crystallographic study of AmtB from Escherichia coli. This electronic density was initially only observed when crystals were grown in presence of ammonium salt and was thus attributed to ammonia (NH(3)) molecules, and lead the authors to suggest that the conduction mechanism in the Amt/Rh p...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813967</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813967</guid>        </item>
        <item>
            <title>[Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience.]</title>
            <link>http://www.medworm.com/index.php?rid=3813965&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674438%26dopt%3DAbstract</link>
            <description>Authors: Petermann R, Piquet Y, Lapeyre M, Goujon N, Gauthier M, Lalanne V, Mouillot L, Tissier MH, Boiron JM
    Since 1998, the Aquitaine-Limousin branch of the French Blood Institute has set up a parvovirus B19 (PV B19) systematic screening on each unit of plasma to be treated by solvent-detergent procedure for virus inactivation. Parvovirus B19 nucleic acid systematic testing in plasma pools became mandatory since 2005 (European monograph &quot;Human plasma&quot; - pooled and treated for virus inactivation). The French competent state authority (AFSSAPS) has decided to introduce this test as a part of the external quality control of labile blood products. This process is related to the harmonization of quality control practice realised on blood products in Europe even if the human plasma pooled ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813965</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813965</guid>        </item>
        <item>
            <title>[Stem cell transplantation in Morocco: Report of 87 cases.]</title>
            <link>http://www.medworm.com/index.php?rid=3813963&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674439%26dopt%3DAbstract</link>
            <description>CONCLUSION: The autologous CSP is simple, effective and well tolerated, which should be developed in our context.
    PMID: 20674439 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813963</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813963</guid>        </item>
        <item>
            <title>[Post-transfusion hepatitis C. From screening to compensation.]</title>
            <link>http://www.medworm.com/index.php?rid=3813961&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674440%26dopt%3DAbstract</link>
            <description>Authors: Ferrant O, Bazin A, Girard A, Le Coutour X, Leporrier M, Papin F
    In France, during the last decades preceding the 1990s, 100,000 to 400,000 blood recipients may have been infected by hepatitis C. Since 1990, thanks to advances in transfusion safety, the risk of hepatitis C contamination has become extremely low. Given the natural history of the disease, it can be a long time unnoticed. Thus, even today, a significant part of infected individuals do not know their serological status. Through several periods and several campaigns, we present the various means used for the detection of post-transfusion hepatitis C at the Caen University Hospital. These methods have been introduced as a result of legislation or through arrangements made by the institution. They were made possible ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813961</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813961</guid>        </item>
        <item>
            <title>[Quality control of defrosted cord blood units: Results from an inter-laboratory study.]</title>
            <link>http://www.medworm.com/index.php?rid=3813959&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20674441%26dopt%3DAbstract</link>
            <description>CONCLUSION: These results underline a good stability of viable CD34+ cells and a greater reliability of the SP methods for the CD34+ cell numeration for these defrosted USP. Lastly, the results of the functional assay regarding the average clonogenicities (equal to 15 %) reinforce the conclusions on the quality of the defrosted products.
    PMID: 20674441 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3813959</comments>
            <pubDate>Wed, 28 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3813959</guid>        </item>
        <item>
            <title>Hereditary spherocytosis.</title>
            <link>http://www.medworm.com/index.php?rid=3798947&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655264%26dopt%3DAbstract</link>
            <description>Authors: Iolascon A, Avvisati RA, Piscopo C
    Hereditary spherocytosis is a common hemolytic disorder characterized by a defect or deficiency in one or more of the proteins composing red blood cell membrane. As a result, red blood cells have an abnormal shape, higher metabolic requirements, and are prematurely trapped and destroyed in the spleen. Hereditary spherocytosis, including the very mild or subclinical forms, is the most common cause of non-immune hemolytic anemia among people of Northern European ancestry, with a prevalence of approximately 1 in 2000. However very mild forms of the disease may be much more common. Hereditary spherocytosis is inherited in a dominant fashion in 75% of cases, whereas the remaining are truly recessive cases and de novo mutations. This review reports...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798947</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798947</guid>        </item>
        <item>
            <title>Diamond-Blackfan anemia, ribosome and erythropoiesis.</title>
            <link>http://www.medworm.com/index.php?rid=3798946&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655265%26dopt%3DAbstract</link>
            <description>Authors: Da Costa L, Moniz H, Simansour M, Tchernia G, Mohandas N, Leblanc T
    Diamond-Blackfan anemia is a rare inherited bone marrow failure syndrome (five to seven cases per million live births) characterized by an aregenerative, usually macrocytic anemia with an absence or less than 5% of erythroid precursors (erythroblastopenia) in an otherwise normal bone marrow. The platelet and the white cell counts are usually normal but neutropenia, thrombopenia or thrombocytosis have been noted at diagnosis. In 40 to 50% of DBA patients, congenital abnormalities mostly in the cephalic area and in thumbs and upper limbs have been described. Recent analysis did show a phenotype/genotype correlation. Congenital erythroblastopenia of DBA is the first human disease identified to result from defects...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798946</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798946</guid>        </item>
        <item>
            <title>The erythroid niche: Molecular processes occurring within erythroblastic islands.</title>
            <link>http://www.medworm.com/index.php?rid=3798944&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655267%26dopt%3DAbstract</link>
            <description>Authors: Mohandas N, Chasis JA
    Erythroblasts terminally differentiate within specialized niches composed of erythroblast islands nesting in extracellular matrix proteins. A number of adhesion molecules active in erythroid island attachments have been identified. We have recently observed a receptor/counter receptor interaction that appears to maintain island integrity: erythroid ICAM-4 interacting with macrophage alphaV integrin. When ICAM-4/alphaV binding is blocked, a 70% decrease in islands is observed. Moreover, erythroblastic islands are markedly decreased in ICAM-4 null mice. Using erythropoietin to examine whether ICAM-4/alphaV binding plays a role in stress erythropoiesis, we found that the reticulocyte response is different in ICAM-4 null mice compared to control mice. We spec...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798944</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798944</guid>        </item>
        <item>
            <title>Erythrocyte adducin: A structural regulator of the red blood cell membrane.</title>
            <link>http://www.medworm.com/index.php?rid=3798943&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655268%26dopt%3DAbstract</link>
            <description>Authors: Franco T, Low PS
    Adducin is an alpha, beta heterotetramer that performs multiple important functions in the human erythrocyte membrane. First, adducin forms a bridge that connects the spectrin-actin junctional complex to band 3, the major membrane-spanning protein in the bilayer. Rupture of this bridge leads to membrane instability and spontaneous fragmentation. Second, adducin caps the fast growing (barbed) end of actin filaments, preventing the tetradecameric protofilaments from elongating into macroscopic F-actin microfilaments. Third, adducin stabilizes the association between actin and spectrin, assuring that the junctional complex remains intact during the mechanical distortions experienced by the circulating cell. And finally, adducin responds to stimuli that may be imp...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798943</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798943</guid>        </item>
        <item>
            <title>Blood group genotyping by high-throughput DNA analysis: Application to the French panel of RBC reagents.</title>
            <link>http://www.medworm.com/index.php?rid=3798942&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655269%26dopt%3DAbstract</link>
            <description>CONCLUSION: Systematic DNA analysis brings important information on reagent red blood cells selection. It can be used at a routine level. Especially, the notion of &quot;antigen of double dose&quot; which is specified in several countries by government bodies should evolve regarding data obtained from DNA analysis. This should improve the quality of reagent red blood cells as first step for antibody identification.
    PMID: 20655269 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798942</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798942</guid>        </item>
        <item>
            <title>Production of erythroid cells from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPS).</title>
            <link>http://www.medworm.com/index.php?rid=3798941&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655785%26dopt%3DAbstract</link>
            <description>Authors: Anstee DJ
    Erythroid progenitors can be generated ex vivo from human embryonic stem cells (hESC) or human induced pluripotent stem cells (hiPS). Development of laboratory scale culture conditions capable of generating mature functional erythrocytes from human embryonic stem cells or human induced pluripotent stem cells would open the possibility for manufacture of therapeutic quantities of red cells and thereby new clinical transfusion products. Current attempts to produce erythrocytes from human embryonic stem cells reveal the need for greater understanding of the process whereby primitive erythropoiesis switches to definitive fetal and adult erythropoiesis and the factors driving erythrocyte maturation. Studies with human embryonic stem cells have already yielded encouraging ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798941</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798941</guid>        </item>
        <item>
            <title>Exosomes in erythropoiesis.</title>
            <link>http://www.medworm.com/index.php?rid=3798940&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655786%26dopt%3DAbstract</link>
            <description>Authors: Vidal M
    Multivesicular endosomes contain membrane vesicles which can be released into the extracellular environment as exosomes. This review describes the role of exosome secretion in the remodeling of the red cell plasma membrane during the last stage of erythropoietic differentiation. Herein, we propose that the exosome biogenesis involves several mechanisms of protein sorting and leads to partial or complete loss of membrane activities, in some cases in a regulated way.
    PMID: 20655786 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798940</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798940</guid>        </item>
        <item>
            <title>Multiple interests in structural models of DARC transmembrane protein.</title>
            <link>http://www.medworm.com/index.php?rid=3798939&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655787%26dopt%3DAbstract</link>
            <description>Authors: Smolarek D, Bertrand O, Czerwinski M, Colin Y, Etchebest C, de Brevern AG
    Duffy Antigen Receptor for Chemokines (DARC) is an unusual transmembrane chemokine receptor which (i) binds the two main chemokine families and (ii) does not transduct any signal as it lacks the DRY consensus sequence. It is considered as silent chemokine receptor, a tank useful for chemiotactism. DARC had been particularly studied as a major actor of malaria infection by Plasmodium vivax. It is also implicated in multiple chemokine inflammation, inflammatory diseases, in cancer and might play a role in HIV infection and AIDS. In this review, we focus on the interest to build structural model of DARC to understand more precisely its abilities to bind its physiological ligand CXCL8 and its malaria ligand....</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798939</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798939</guid>        </item>
        <item>
            <title>Red blood cell proteomics.</title>
            <link>http://www.medworm.com/index.php?rid=3798938&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655788%26dopt%3DAbstract</link>
            <description>Authors: Pasini EM, Mann M, Thomas AW
    Since its discovery in the 17th century, the red blood cell, recognized in time as the critical cell component for survival, has been the focus of much attention. Its unique role in gas exchange (oxygen/CO(2) transport) and its distinct characteristics (absence of nucleus; biconcave cell shape) together with an - in essence - unlimited supply lead to extensive targeted biochemical, molecular and structural studies. A quick PubMed query with the word &quot;erythrocyte&quot; results in 198 013 scientific articles of which 162 are red blood cell proteomics studies, indicating that this new technique has been only recently applied to the red blood cell and related fields. Standard and comparative proteomics have been widely used to study different blood componen...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798938</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798938</guid>        </item>
        <item>
            <title>Role of Lu/BCAM glycoproteins in red cell diseases.</title>
            <link>http://www.medworm.com/index.php?rid=3798937&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655789%26dopt%3DAbstract</link>
            <description>Authors: El Nemer W, Colin Y, Le Van Kim C
    Lu/BCAM glycoproteins (gps) are the unique erythroid receptors of laminin alpha5 chain, a major component of the extracellular matrix. They interact with the membrane skeleton by binding directly to spectrin via the Lu/BCAM RK573-574 motif. Lu/BCAM gps are involved in abnormal sickle red blood cell (RBC) adhesion to components of the vascular wall. This adhesion is activated by the phosphorylation of the Lu/BCAM long isoform Lu in a protein kinase A-dependent manner. A similar high adhesion to laminin was also observed with RBCs from Hereditary Spherocytosis (HS) patients suffering from haemolytic anaemia subsequent to spectrin deficiencies. We investigated the molecular mechanisms responsible for the Lu/BCAM-mediated abnormal RBC adhesion to ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798937</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798937</guid>        </item>
        <item>
            <title>Plasmodium vivax and the Duffy antigen: A paradigm revisited.</title>
            <link>http://www.medworm.com/index.php?rid=3798936&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655790%26dopt%3DAbstract</link>
            <description>Authors: Mercereau-Puijalon O, MÃ©nard D
    The Duffy blood group antigen is the portal of entry of the Plasmodiumvivax malaria parasite into human red blood cells and the receptor for a number of CXC and CC chemokines. We review here epidemiological data and evidence derived from therapeutic or experimental human infections associating P. vivax and the Duffy glycoprotein and laboratory studies indicating that P. vivax uses the Duffy antigen as a receptor to invade the red cell. We then review recent field observations indicating that the conclusion of the absolute dependence on the presence of Duffy on the red cell for P. vivax infection and development into the red cell no longer holds true and that in some parts of the world, P. vivax infects and causes disease in Duffy-negative peop...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798936</comments>
            <pubDate>Wed, 21 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798936</guid>        </item>
        <item>
            <title>Rac GTPases in erythroid biology.</title>
            <link>http://www.medworm.com/index.php?rid=3798945&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20655266%26dopt%3DAbstract</link>
            <description>Authors: Konstantinidis DG, George A, Kalfa TA
    Rac1 and Rac2 GTPases, members of the Rho GTPases family, control actin organization and play distinct and overlapping roles in hematopoietic and mature blood cells of all lineages. Here, we review our findings on the role of Rac GTPases in erythroid cells, by using conditional gene-targeting in mice. Rac1 and Rac2 deficiency causes anemia with reticulocytosis, indicating decreased red blood cell (RBC) survival, altered actin assembly in the erythrocyte membrane skeleton and decreased RBC deformability. On the other hand, Rac1(-/-); Rac2(-/-) megakaryocyte-erythrocyte progenitors demonstrate decreased proliferation in the bone marrow, but increased survival and proliferation in the spleen, indicating that stress erythropoiesis circumvents ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3798945</comments>
            <pubDate>Tue, 20 Jul 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3798945</guid>        </item>
        <item>
            <title>[Adverse unidentified transfusion reactions in five French regions: Analysis, results, propositions.]</title>
            <link>http://www.medworm.com/index.php?rid=3280713&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153674%26dopt%3DAbstract</link>
            <description>CONCLUSION: The study confirms the necessity to re-examine the French notification system. It underlines the insufficiency of clinical and biological investigations, which could allow to reach accurate diagnosis. It gives prominence the necessity of taking into account the patient's pathology and targets at least two diagnoses of transfusion adverse effects which are not yet proposed on the FEIR model. This work brings an overture about evolution of the French haemovigilance database which will involve further developments.
    PMID: 20153674 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3280713</comments>
            <pubDate>Thu, 11 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3280713</guid>        </item>
        <item>
            <title>[Analysis of a severe septic transfusion reaction with standard platelet concentrate.]</title>
            <link>http://www.medworm.com/index.php?rid=3221481&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20106699%26dopt%3DAbstract</link>
            <description>Authors: Courbil R, Romaszko JP, Odent-Malaure H, Fabrigli P, Chavarin P, Tournilhac O, Bay JO, Fressy P, Ergani A, Bouvet A, Bonnet R, Garraud O
    We recently observed a near fatal case of transfusion-transmitted infection with standard platelet concentrate. Streptococcus dysgalactiae subspecies equisimilis was isolated both from donor, residual component container and cultures of the patient's blood. This should question the usefulness of systematic bacterial detection in platelet concentrates, however a lethal accident has occurred recently which escaped bacterial detection. This observation calls for implementation of pathogen inactivation procedures for platelets concentrates.
    PMID: 20106699 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3221481</comments>
            <pubDate>Mon, 25 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3221481</guid>        </item>
        <item>
            <title>[The effect of leukocyte-reduction on the transfusion reactions to red blood cells concentrates.]</title>
            <link>http://www.medworm.com/index.php?rid=3221480&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20106700%26dopt%3DAbstract</link>
            <description>CONCLUSION: Universal leukocyte reduction significantly reduced the rate of transfusion reactions.
    PMID: 20106700 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3221480</comments>
            <pubDate>Mon, 25 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3221480</guid>        </item>
        <item>
            <title>[Reorganization of blood watch and transfusion safety activities in the Marseille public hospital system in partnership between the French blood institute Alps Mediterranean division (EFS AM).]</title>
            <link>http://www.medworm.com/index.php?rid=3221479&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20106701%26dopt%3DAbstract</link>
            <description>Authors: Lassale B, Legrand D, Chiaroni J
    The Marseille public hospital system (APHM) has expressed its willingness to pool its services of immunohematology and delivery of labile blood products with those of the French blood institute Alps Mediterranean division (EFS AM). An agreement setting out the terms of this partnership was signed between the two parties. The users of the APHM and EFS AM blood watch wished to preserve the channels of distribution. Implementation of this reorganization has focused on ensuring transfusional safety, reinforcing harmonization of APHM practices, and finding ways to reduce costs. Despite joint information campaigns (to medical and paramedical personnel) carried out by the APHM and EFS AM blood watch, problems have arisen during start-up and adjustment...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3221479</comments>
            <pubDate>Mon, 25 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3221479</guid>        </item>
        <item>
            <title>[Karl Landsteiner discovers the blood groups.]</title>
            <link>http://www.medworm.com/index.php?rid=3136507&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20044293%26dopt%3DAbstract</link>
            <description>Authors: Lefr&amp;#xE8;re JJ, Berche P
    The discovery of ABO blood group was a major step in mastering transfusion therapy. Karl Landsteiner (1868-1843) was the author of this discovery. This paper retraces the hard career of this American scientist of Austrian origin, and describes the circumstances that led his research to the discoveries, which were turning points in the history of the immunology.
    PMID: 20044293 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3136507</comments>
            <pubDate>Tue, 29 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3136507</guid>        </item>
        <item>
            <title>[Extracorporeal photochemotherapy.]</title>
            <link>http://www.medworm.com/index.php?rid=3136508&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20042357%26dopt%3DAbstract</link>
            <description>Authors: Viguier M, Pouthier F, Tiberghien P, Aubin F
    Photopheresis or extracorporeal photochemotherapy (ECP) is a cellular therapy which combines a leukapheresis followed by ex vivo treatment using psoralen and ultraviolet A irradiation before reinfusion into the patient. Its mechanisms of action remain unclear and selective photodestruction of leukocytes cannot explain the long-lasting immunomodulatory effects. Recent studies demonstrated that ECP down regulates the immune response and induces tolerance through the maturation of dendritic cells and the production of regulatory T cells. Based on these effects, ECP is mainly used for treatment of Sezary syndrome, graft-versus-host disease, organ graft rejection and autoimmune diseases. However, it is still not clear how ECP both activa...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3136508</comments>
            <pubDate>Mon, 28 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3136508</guid>        </item>
        <item>
            <title>[Process design method for a multicreteria performance: Application to the French Blood Establishment.]</title>
            <link>http://www.medworm.com/index.php?rid=3027974&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19932630%26dopt%3DAbstract</link>
            <description>Authors: Sghaier W, Hergon E, Bocquet JC, Desroches A
    The organisations' performance is not restricted to economic criteria, it integrates other dimensions: social, safety, quality, environmental, ethical, scientific... There are few multicriteria design and management methods for organisations. In this article, we propose an analysis and modelling method of the values creation based on systematic approach. This method enables to integrate all the stakeholders' points of view and expectations in order to have a global vision of the performance. We have applied this method to one French Blood Establishment process.
    PMID: 19932630 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3027974</comments>
            <pubDate>Fri, 20 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3027974</guid>        </item>
        <item>
            <title>[Blood transfusion current situation in francophone African Countries: Do the North and South point of views fit together ?]</title>
            <link>http://www.medworm.com/index.php?rid=3027973&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19932631%26dopt%3DAbstract</link>
            <description>Authors: Garraud O, Andreu G
    
    PMID: 19932631 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3027973</comments>
            <pubDate>Fri, 20 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3027973</guid>        </item>
        <item>
            <title>[Ex vivo expansion of hematopoietic stem cells: Concept and clinical benefit.]</title>
            <link>http://www.medworm.com/index.php?rid=3027972&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19932632%26dopt%3DAbstract</link>
            <description>Authors: Ivanovic Z, Boiron JM
    A new discipline was born and grew up over the last 4 decades of 20th century: Experimental Hematology. In addition to yield the concept of Stemness, a paradigm later applied for the other tissues than hematopoietic one, it provided the results allowing a preclinical development and a therapeutic exploitation. The concept of ex vivo expansion of hematopoietic cells for transplantation is directly issued from this knowledge. It enabled us to realize that a critical quantity of different sub-populations of stem and progenitor cells are necessary to obtain a rapid and sustained hematopoietic reconstitution. These principles, transposed to human cells (originating from: bone marrow, peripheral blood, cord blood) required some important technological innovatio...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3027972</comments>
            <pubDate>Fri, 20 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3027972</guid>        </item>
        <item>
            <title>[Residual risk of transmission of HIV and HCV, in Senegalese national blood bank from 2003 to 2005.]</title>
            <link>http://www.medworm.com/index.php?rid=3017325&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19926508%26dopt%3DAbstract</link>
            <description>CONCLUSION: It emerges from this study that the risk of blood transmitted virus is always high. Introduction of more sensitive tests (as nucleic acid testing) would allow us to deliver more safety products.
    PMID: 19926508 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3017325</comments>
            <pubDate>Mon, 16 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3017325</guid>        </item>
        <item>
            <title>HIV, HCV, HBV and syphilis rate of positive donations among blood donations in Mali: Lower rates among volunteer blood donors.</title>
            <link>http://www.medworm.com/index.php?rid=2981524&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19896404%26dopt%3DAbstract</link>
            <description>Authors: Diarra A, Kouriba B, Baby M, Murphy E, Lefrere JJ
    Good data on background seroprevalence of major transfusion transmitted infections is lacking in Mali. We gathered data on the rate of positive donations of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) and syphilis among blood donations in Mali for calendar year 2007. Donations with repeatedly reactive results on screening enzyme immunoassay (EIA) were considered to be seropositive. Rate of positive donations per blood unit collected was 2.6% for HIV, 3.3% for HCV, 13.9% for hepatitis B surface antigen (HBsAg) and 0.3% for syphilis. For HIV, HBsAg and syphilis, rate of positive donations was significantly (p&amp;lt;0.001) higher among donations from replacement donors than those from voluntee...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2981524</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2981524</guid>        </item>
        <item>
            <title>[Situation and perspectives of blood transfusion in Togo.]</title>
            <link>http://www.medworm.com/index.php?rid=2981523&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19896405%26dopt%3DAbstract</link>
            <description>We report the successive stages of the reorganization of the blood transfusion sector in Togo. The starting point was the elaboration of the national policy of blood transfusion, then the adoption of a decree organizing the sector as well the various decree of application, particularly that related to transfusion good practices. The current policy recommends two poles of qualification of the blood ant its components and the creation of six stations of collection and distribution attached to these poles. The reorganization started with the rehabilitation of the National Blood Transfusion Centre (CNTS) in Lom&amp;#xE9;. If the problem of human resources is alarming, especially the availability of hemobiologists, the rehabilitation allowed the increase of the blood collection passing from 5272 do...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2981523</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2981523</guid>        </item>
        <item>
            <title>[Contribution of electronic data interchange to haemovigilance in a hospital - Experience in the University Hospital of Reims.]</title>
            <link>http://www.medworm.com/index.php?rid=2955622&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19880338%26dopt%3DAbstract</link>
            <description>CONCLUSION: Although the new process was supposed to be more efficient and easier for the user, the global result on traceability by users is negative after 18months.
    PMID: 19880338 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2955622</comments>
            <pubDate>Fri, 30 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2955622</guid>        </item>
        <item>
            <title>[Genetic diversity of human erythroviruses. Consequences on infectious safety of plasma derivatives.]</title>
            <link>http://www.medworm.com/index.php?rid=2955621&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19880339%26dopt%3DAbstract</link>
            <description>Authors: Servant-Delmas A, Mercier M, Laperche S, Lefr&amp;#xE8;re JJ
    The B19 Parvovirus (B19V) has for a long time been considered as the unique human virus belonging to the genus Erythrovirus. The genetic diversity of B19V isolates has been shown to be very low. The isolation of a variant (V9 strain), with a sequence markedly distinct from that of B19V which led to attributing this classification to this family of viruses. Phylogenetic analysis of sequences of V9-related isolates indicates an organization into three well-individualized genotypes. The B19V infection can be transmitted by transfusion. In immunocompetent recipients, B19V exposure by transfusion is most often inconsequential, since a large proportion is immunized. Such an infection may have serious clinical outcome in not im...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2955621</comments>
            <pubDate>Fri, 30 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2955621</guid>        </item>
        <item>
            <title>[Kidney transplantation in patient with haemophilia A.]</title>
            <link>http://www.medworm.com/index.php?rid=2955623&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19879788%26dopt%3DAbstract</link>
            <description>Authors: El Bakkouri J, Mamdouh A, Faez S, Medkouri G, Ramdani B, Benchemsi N
    A 37-year-old patient with moderate haemophilia A and end-stage renal disease underwent kidney transplantation in the University Hospital Ibn Rochd of Casablanca (Morocco). He received factor VIII replacement therapy perioperatively and until the 21st day postoperation. So, the activity rates of Factor VIII was higher than or equal to 80 % in the day of intervention and two to three days later, then between 30 and 60 % until healing. The evolution of the patient to 28 months post-transplantation is marked by a good renal function without episode of rejection or bleeding complications. The heavy surgical interventions are possible in patients with haemophilia, but depend on good replacement therapy in peri- an...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2955623</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2955623</guid>        </item>
        <item>
            <title>[The transfusion center, the blood donor and the given blood in francophone African countries.]</title>
            <link>http://www.medworm.com/index.php?rid=2843157&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19783191%26dopt%3DAbstract</link>
            <description>Authors: Tayou Tagny C, Diarra A, Yahaya R, Hakizimana M, Nguessan A, Mbensa G, N&amp;#xE9;bi&amp;#xE9; Y, Dahourou H, Tapko JB, Shiboski C, Murphy E, Lefr&amp;#xE8;re JJ
    In subsaharan Africa, knowledge of the organization and methods of transfusion centers, as well as blood donor characteristics, is essential in choosing strategies to improve transfusion practices and the security of blood products on this Continent. The present study was based on a analysis led in partnership with the transfusion of seven francophone African countries (Burkina-Faso, Cameroon, Congo, Ivory Cost, Mali, Niger, and Rwanda). The results showed that withstanding significant progress has been realized in the organization and safety, but much remains to be undertaken over the years to come in order to improve the organi...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2843157</comments>
            <pubDate>Thu, 24 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2843157</guid>        </item>
        <item>
            <title>[How to manage analysis and feedback of adverse events in transfusion.]</title>
            <link>http://www.medworm.com/index.php?rid=2843158&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19782626%26dopt%3DAbstract</link>
            <description>Authors: Roussel P, Moll MC, Lassale B, Ragni J
    Analysing adverse events is part of the medical practice in so far as the part it plays is outstanding in terms of feedback and improved healthcare safety. The integrated implementation of this practice is based on a four-dimensional system: strategic (corporate policies), cultural (safety-oriented cultural mindset), structural (dedicated organization and resources) and technical (methodologies and utilities). Two case studies illustrate the sequencing process from selecting the to-be-analyzed event down to figuring out the appropriate action plan. Beyond the visible and obvious origin, thanks to the implemented methods such as causal tree or ALARM method, far-fetched analysis elements and identified factors likely to explain events can b...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2843158</comments>
            <pubDate>Wed, 23 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2843158</guid>        </item>
        <item>
            <title>RBC alloimmunization is an important complication of FFP transfusion: A case report of immune anti-D induced by apheresis fresh frozen plasma.</title>
            <link>http://www.medworm.com/index.php?rid=2801195&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19748813%26dopt%3DAbstract</link>
            <description>We report a female group A, D- patient with cerebrovascular disease who was induced to develop IgG immune anti-D which can be detected on the 15th day of hospitalization after the relatively regular time interval of transfusion of 1800ml apheresis FFP. Therefore, in making clinical decisions to transfuse FFP or apheresis FFP, the best choice is considered as the same or compatibility with RhD group, in case Rh immunization can be induced and trigger some potential serious problems in future emergent transfusion or pregnancy, especially in high incidence of D antigen countries.
    PMID: 19748813 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2801195</comments>
            <pubDate>Thu, 10 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2801195</guid>        </item>
        <item>
            <title>[The red blood cell antigen terminologies.]</title>
            <link>http://www.medworm.com/index.php?rid=2753174&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19716739%26dopt%3DAbstract</link>
            <description>Authors: Peyrard T, Rouger P
    Since the discovery of blood groups in humans, several hundred new red blood cell antigens have been identified. Multiple terminology modes have been used to denote each new antigen identified, but without any consistent rules, nor international consensus. This was largely due to the many discoverers of these antigens, using either letters of the alphabet, numbers, part of the patient or donor's name, place of discovery or animal names. Besides, alternative terminologies for the Rh system were implemented in the middle of the twentieth century (Rosenfield, Fisher-Race, Wiener). The International Society of Blood Transfusion described for the first time in 1980 the advantages of an alphanumeric and homogeneous nomenclature, keeping with the genetic bases of ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753174</comments>
            <pubDate>Wed, 26 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753174</guid>        </item>
        <item>
            <title>[Screening of syphilis in the Subsaharan African blood donor: Which strategy?]</title>
            <link>http://www.medworm.com/index.php?rid=2725649&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19695921%26dopt%3DAbstract</link>
            <description>Authors: Tagny CT
    In a context of high prevalence of syphilis in blood donor and of resources-limited settings, this review aims to describe biological elements which are available for the screening of the disease and the essentials considerations which participate to choose a screening test in subsaharan Africa. Treponemics, non treponemics, immunochromatographics or nucleic, the type of the chosen screening test must contribute to the blood transfusion safety as well as be affordable.
    PMID: 19695921 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2725649</comments>
            <pubDate>Mon, 17 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2725649</guid>        </item>
        <item>
            <title>[Prevention of transfusion transmitted malaria in endemic area.]</title>
            <link>http://www.medworm.com/index.php?rid=2692793&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19665412%26dopt%3DAbstract</link>
            <description>CONCLUSION: Plasmodium represents the third risk of blood transmitted infectious agents after hepatitis B virus, syphilis, and before HCV and HIV in Senegal. The medical questionnaire is not useful enough for asymptomatic carriers deferral, and we propose to introduce Plasmodium screening. The screening for Plasmodium pLDH by Elisa technique seems to be the best tool in endemic area and the strategy of systematic screening is the most suited in terms of blood transfusion safety.
    PMID: 19665412 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2692793</comments>
            <pubDate>Wed, 05 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2692793</guid>        </item>
        <item>
            <title>The role and impact of the transfusion medicine consultation service in the management of patients in the hematopoietic transplant service: A retrospective analysis.</title>
            <link>http://www.medworm.com/index.php?rid=2692792&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19665413%26dopt%3DAbstract</link>
            <description>CONCLUSION: Use of these safety tools has improved the safety culture regarding transfusion of blood components in hematopoietic transplant recipients at our institution.
    PMID: 19665413 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2692792</comments>
            <pubDate>Wed, 05 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2692792</guid>        </item>
        <item>
            <title>[Teaching transfusion medicine research in the francophone world.]</title>
            <link>http://www.medworm.com/index.php?rid=2661272&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19640755%26dopt%3DAbstract</link>
            <description>Authors: Lefr&amp;#xE8;re JJ, Shiboski C, Fontanet A, Murphy EL
    A two-week, French language, clinical research course in transfusion medicine has recently been created at the Pasteur Institute in Paris under the joint leadership of faculty members from the University of California San Francisco (UCSF), the Blood Systems Research Institute (BSRI) and the National Institute of Transfusion of Paris. The goal is to train transfusion professionals from the developing world to conduct clinical research that will contribute to improving the quality of care and safety in transfusion practices in their respective countries. The course provides training on clinical and epidemiological research methods and their potential applications in transfusion medicine. As part of the course, each student devel...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2661272</comments>
            <pubDate>Sun, 26 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2661272</guid>        </item>
        <item>
            <title>[A one-year survey of an emergency released group O red blood cell stock used by a surgical treatment center.]</title>
            <link>http://www.medworm.com/index.php?rid=2661271&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19640756%26dopt%3DAbstract</link>
            <description>CONCLUSION: The concentrates, used by the anaesthesiologists, are part of the treatment strategy care in case of severe bleeding.
    PMID: 19640756 [PubMed - as supplied by publisher] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2661271</comments>
            <pubDate>Sun, 26 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2661271</guid>        </item>
        <item>
            <title>[Cell culture for transfusion purposes: The concept of &quot;cultured red blood cells&quot;]</title>
            <link>http://www.medworm.com/index.php?rid=2533692&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19375969%26dopt%3DAbstract</link>
            <description>[Cell culture for transfusion purposes: The concept of &quot;cultured red blood cells&quot;]
    Transfus Clin Biol. 2009 May;16(2):134-137
    Authors: Douay L
    One has been trying for several years to find a substitute for red blood cells (RBC). The development of chemical or natural molecules to replace hemoglobin has nevertheless proved difficult and artificial blood is still unattainable. We have described a methodology permitting the massive ex vivo production of mature human RBC having all the characteristics of native adult RBC from hematopoietic stem cells (HSC) of diverse origins: blood, bone marrow or cord blood. This protocol allows both massive expansion of the HSC/progenitors and their complete differentiation to the stage of perfectly functional mature RBC. The levels of amplificat...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533692</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533692</guid>        </item>
        <item>
            <title>[Genotyping of blood group systems at the CNRGS. I: FY, JK, MNS systems.]</title>
            <link>http://www.medworm.com/index.php?rid=2533690&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19386532%26dopt%3DAbstract</link>
            <description>CONCLUSION: Usefulness of blood group genotyping in specialized immunohematology laboratories is obvious. However, the strategy for implementation of molecular methods remains to be defined. Use of high-throughput DNA analysis should change our way of working.
    PMID: 19386532 [PubMed - in process] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533690</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533690</guid>        </item>
        <item>
            <title>[Immune thrombocytopenic purpura: Pathophysiology and treatment.]</title>
            <link>http://www.medworm.com/index.php?rid=2533688&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19409827%26dopt%3DAbstract</link>
            <description>Authors: Godeau B
    Immune thrombopenic purpura (ITP) is an autoimmune disease characterized by a peripheral destruction of platelets. B lymphocytes play a key role but pathophysiology is more complex, involving humoral and cellular immunity associated with an inappropriate platelet production. The treatment of ITP is still based on uncontrolled studies. Prednisone and intravenous immunoglobulins remain the first line treatments. Splenectomy remains the best &quot;curative&quot; treatment for adults with chronic ITP. However, most patients are reluctant to undergo surgery and new treatments give promising results. Among them, rituximab and thrombopoietin receptor agonists could replace splenectomy in near future.
    PMID: 19409827 [PubMed - as supplied by publisher] (Source: Transfusion Clinique ...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533688</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533688</guid>        </item>
        <item>
            <title>[Fetal/neonatal alloimmune thrombocytopenias.]</title>
            <link>http://www.medworm.com/index.php?rid=2533686&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19409828%26dopt%3DAbstract</link>
            <description>Authors: Kaplan C
    Fetal and neonatal alloimmune thrombocytopenias result from maternal immunization against fetal specific platelet antigens inherited from the father that the mother lacks. The incidence has been estimated to one in 800 to one in 1000 live births. The most feared complication in case of severe thrombocytopenia is the occurrence of intracranial hemorrhage, leading to death or neurological sequelea. The diagnosis is straightforward when a maternal alloantibody is detected and the offending antigen identified in the infant. Any difficulties in confirming the diagnosis should not delay the treatment. Since the first description of these conditions in the 1950's, significant progress has been made in laboratory diagnosis and management.
    PMID: 19409828 [PubMed - in proce...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533686</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533686</guid>        </item>
        <item>
            <title>[Genotyping applied to platelet immunology: When? How? Limits.]</title>
            <link>http://www.medworm.com/index.php?rid=2533684&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19409829%26dopt%3DAbstract</link>
            <description>Authors: Bertrand G, Kaplan C
    Platelet alloantigens named Human Platelet Antigens (HPA) are involved in immune conflicts such as post-transfusion purpura, platelet transfusion refractoriness and neonatal alloimmune thrombocytopenia. Biological diagnosis relies on: (1) detection of alloantibodies; (2) identification of the alloantigen involved in the immune conflict. Since the development of methods based on molecular biology, platelet genotyping is preferred to phenotyping. Today, most of the Platelet Immunology Units use PCR-RFLP or PCR-SSP, and few use real-time PCR. An increasing amount of commercial kits based on new technologies is now available, for example microarrays, fluorescent or coloured microbeads, or a combination of both technologies. However, an increasing number of pol...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533684</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533684</guid>        </item>
        <item>
            <title>[Quantitative estimate of the risk of blood donation contamination by infectious agents.]</title>
            <link>http://www.medworm.com/index.php?rid=2533682&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19409830%26dopt%3DAbstract</link>
            <description>The objective of this article is to update the last estimates of residual risks of the major transfusion-transmitted viral infections (HIV, HTLV, HCV and HBV) and to present the work realized by the working group &amp;lt;&amp;lt; Quantitative estimate of the risk of blood donation contamination by infectious agents&amp;gt;&amp;gt;.
    PMID: 19409830 [PubMed - in process] (Source: Transfusion Clinique et Biologique)</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533682</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533682</guid>        </item>
        <item>
            <title>[Immunohematological surveillance of the pregnant woman: New prevention policy.]</title>
            <link>http://www.medworm.com/index.php?rid=2533681&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19419894%26dopt%3DAbstract</link>
            <description>Authors: Mannessier L
    Despite the generalization of immunoprophylaxis by anti-RH immunoglobulins over 40 years, fetomaternal incompatibility due to RH1 antigen (RhD) is not completely eradicated, although perinatal consequences might be extremely serious. Additionally, allo-immunizations against other antigens, especially anti-RH4 (anti-c) and anti-KEL1 (anti-Kell), may cause severe haemolytic disease. Follow-up of allo-immunization during pregnancy and its prevention are therefore still a concern for all pregnant women. Immunohaematological tests used in antenatal patients are under practice for a long time. However, despite significant progress, it is clear that these tests provide only an indirect indication and will only help the obstetrician, in conjunction with over fetal paramet...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533681</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533681</guid>        </item>
        <item>
            <title>Protecting the blood supply from emerging pathogens: The role of pathogen inactivation.</title>
            <link>http://www.medworm.com/index.php?rid=2533680&amp;cid=s_36126_19_f&amp;fid=36126&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19427252%26dopt%3DAbstract</link>
            <description>Authors: Blajchman MA
    As a consequence of the many blood-safety interventions introduced since the mid-1980s, the major causes of transfusion-associated mortality have shifted from being mainly due to transfusion-transmitted infections (TTIs) to being mainly due to non-infectious serious events such as TRALI, hemolytic reactions, transfusion overload, and graft versus host disease. Thus, TTIs now account for only 10 to 15% of all transfusion associated mortalities! Relevantly, manufacturers of purified plasma protein fractions have, over the same time period, shown that pathogen inactivation technologies can be successfully implemented resulting in little or no transmission of HIV, HCV or HBV since the late 1980s. These technologies, however, cannot be applied to cellular blood compone...</description>
            <author>Transfusion Clinique et Biologique</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2533680</comments>
            <pubDate>Thu, 30 Apr 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2533680</guid>        </item>
    </channel>
</rss>

